Protagenic Therapeutics (PTIX) S-1/A 27 Jan 17 2016 Q3 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 17, 2016
Document Information [Line Items]
Entity Registrant Name	Protagenic Therapeutics, Inc.\new
Entity Central Index Key	1,022,899
Trading Symbol	atrn
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		8,307,915
Document Type	S-1/A
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Amendment Flag	true
Amendment Description	On February 12, 2016, Artinsic, Inc., a Delaware corporation, (“Atrinsic”) completed a reverse business combination (merger) whereby Atrinsic’s wholly-owned subsidiary Protagenic Acquisition Corp. was merged with and into Protagenic Therapeutics, Inc., a Delaware corporation, and Protagenic Therapeutics, Inc. became the wholly-owned subsidiary of Atrinsic. On June 17, 2016, Protagenic Therapeutics, Inc. (the then wholly-owned subsidiary of Atrinsic) was merged with and into Atrinsic. Atrinsic was the surviving corporation in this merger and changed its name from Atrinsic to Protagenic Therapeutics, Inc. As used in this prospectus, the terms the “Company,” “we,” “us,” and “our” refer to Protagenic Therapeutics, Inc. after giving effect to the mergers. The terms “Atrinsic” and “Predecessor” refer to Atrinsic, Inc. before giving effect to the mergers, and the term “Protagenic” refers to Protagenic Therapeutic, Inc. before giving effect to the mergers.

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 3,488,978	$ 3,343
Prepaid expenses	96,667
TOTAL CURRENT ASSETS	3,585,645	3,343
Computer	1,271	1,712
OTHER ASSETS		6,230
TOTAL ASSETS	3,586,916	11,142
CURRENT LIABILITIES
Bridge Loan Payable - Stockholder and accrued interest		399,103
Accounts payable and accrued expenses	131,568	276,532
Derivative liability	516,757
TOTAL CURRENT LIABILITIES	648,325	678,358
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, par value
Common stock at $.001 par value, 20,000,000 shares authorized; 7,613,338 shares issued and 6,613,338 outstanding for December 31, 2015 and 2014	831	7,613
Additional paid-in-capital	11,137,911	5,880,119
Accumulated deficit	(8,026,046)	(6,306,297)
Treasury stock, at cost $.001 par value, 1,000,000 shares, for December 31, 2015 and 2014		(100,000)
Accumulated other comprehensive loss	(174,108)	(148,651)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	2,938,591	(667,216)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	3,586,916	11,142
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, par value	$ 0.000001	$ 0.000001

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.000001	$ 0.000001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, par value
Common Stock, Par Value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized (in shares)	100,000,000	20,000,000
Common Stock, Shares Issued (in shares)	8,307,915	7,612,838
Common Stock, Shares Outstanding (in shares)	8,307,915	6,612,838
Treasury Stock, Par Value	$ 0.001	$ 0.001
Treasury Stock, Shares (in shares)	1,000,000	1,000,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	18,000,000	18,000,000
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares issued (in shares)	2,796,929	0
Preferred stock, shares outstanding (in shares)	2,796,929	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
REVENUE				$ 0	$ 0	$ 0	$ 0
OPERATING AND ADMINISTRATIVE EXPENSES
Research and development	114,941	203,814	265,238	537,662		456,274	191,069
General and administrative expenses	339,886	157,025	246,485	735,394		568,764	101,031
Goodwill impairment				404,169
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES	454,827	360,839	511,723	1,677,225		1,025,038	292,100
LOSS FROM OPERATIONS	(454,827)	(360,839)	(511,723)	(1,677,225)		(1,025,038)	(292,100)
OTHER INCOME (EXPENSE)
Interest income	332			611			49
Interest expense - stockholder				(7,161)	(11,473)	(11,473)
Foreign currency exchange gain (loss)	(43)	(78,638)	(74,664)	(6,642)		13,089	(10,430)
Change in fair value of derivative liability	(938)			(29,332)
TOTAL OTHER INCOME (EXPENSE)	(649)	(78,638)	(74,664)	(42,524)		1,616	(10,381)
NET LOSS	(455,476)	(439,477)	(586,387)	(1,719,749)	$ (586,387)	(1,023,422)	(302,481)
COMPREHENSIVE LOSS
Foreign exchange translation loss	(47,750)	(7,816)	(7,925)	(25,457)		(1,070)	(156,338)
TOTAL COMPREHENSIVE LOSS	$ (503,226)	$ (447,293)	$ (594,312)	$ (1,745,206)		$ (1,024,492)	$ (458,819)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.06)	$ (0.07)	$ (0.09)	$ (0.45)		$ (0.15)	$ (0.05)
Weighted average common shares - basic and diluted (in shares)	7,956,625	6,612,838	6,612,838	3,826,068		6,613,338	6,613,338

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series B Preferred Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Common Stock [Member]	Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Series B Preferred Stock [Member]Retained Earnings [Member]	Series B Preferred Stock [Member]Treasury Stock [Member]	Series B Preferred Stock [Member]AOCI Attributable to Parent [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	AOCI Attributable to Parent [Member]	Total
BALANCE (in shares) at Dec. 31, 2013								7,613,338
BALANCE at Dec. 31, 2013								$ 7,613	$ 5,316,322	$ (4,980,394)		$ 8,757	$ 252,298
Stock Issued During Period, Shares, New Issues								0
Stock compensation - stock options									85,168				85,168
Net Loss										(302,481)			(302,481)
BALANCE (in shares) at Dec. 31, 2014								7,613,338
BALANCE at Dec. 31, 2014								$ 7,613	5,401,490	(5,282,875)		(147,581)	(121,353)
Stock Issued During Period, Shares, New Issues								0
Stock compensation - stock options									478,629				478,629
Net Loss										(1,023,422)			(1,023,422)
BALANCE (in shares) at Dec. 31, 2015								7,612,838			(1,000,000)
BALANCE at Dec. 31, 2015								$ 761	5,886,971	(6,306,297)	$ (100,000)	(148,651)	(667,216)
Atrinsic shares converted (in shares)	297,468							25,867
Atrinsic shares converted	$ 1							$ 3	63,381				63,385
Protagenic shares converted (in shares)	6,612,838							(7,612,838)			1,000,000
Protagenic shares converted	$ 6							$ (761)	(99,245)		$ 100,000
Warrants issued for exchange of debt									340,784				340,784
Stock Issued During Period, Shares, New Issues	4,108,460
Stock Issued During Period, Value, New Issues	$ 4								4,761,793				4,761,797
Warrants issued to placement agent									146,641				146,641
Reclassification of warrants to derivative liability									(487,425)				(487,425)
Foreign currency translation (loss)												(25,457)	(25,457)
Stock compensation - stock options									450,566				450,566
Conversion of series B Preferred Stock (in shares)	(8,221,837)	8,221,837						60,211
Conversion of series B Preferred Stock	$ (8)	$ 822	$ (814)					$ 6	75,259				75,265
Net Loss										(1,719,749)			(1,719,749)
BALANCE (in shares) at Sep. 30, 2016	2,796,929							8,307,915
BALANCE at Sep. 30, 2016	$ 3							$ 831	$ 11,137,911	$ (8,026,046)		$ (174,108)	$ 2,938,591

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net Loss	$ (1,719,749)	$ (586,387)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	379	107
Goodwill impairment	404,169
Stock based compensation	450,566	358,972
Interest added to bridge loan	7,161	11,473
Legal fees satisfied through issuance of Series B preferred stock	150,000
Change in fair value of the derivative liability	29,332
Changes in operating assets and liabilities
Prepaid expenses	(96,667)
Other receivables	6,428	(321)
Other assets		4,147
Accounts payable and accrued expenses	(30,131)	51,893
NET CASH USED IN OPERATING ACTIVITIES	(798,511)	(160,116)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock		214,149
Proceeds from bridge loan	19,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,302,437	214,149
Effect of exchange rate on cash and cash quivalents	(18,291)	(17,916)
NET DECREASE IN CASH AND CASH EQUIVALENTS	3,485,635	36,117
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	3,343	22,733
CASH AND CASH EQUIVALENTS, END OF YEAR	3,488,978	58,850
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest expense
Cash paid for income taxes
NONCASH TRANSACTIONS
Warrants issued to placement agent	146,641
Warrants issued for Atrinsic debt settlement and conversion	340,784
Debt settled with issuance of Series B preferred stock	425,265
Reclassification of warrants to derivative liabilities from equity	487,425
Accrued liabilities paid through the issuances of Series B preferred stock	125,000
Series B Preferred stock converted to common stock	8
Goodwill Acquired through Stock Issuance to Predecessor Stockholders [Member]
NONCASH TRANSACTIONS
Goodwill recognized in connection with reverse business combination	404,169
Series B Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Series B Preferred Stock	$ 4,283,437

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 3,343	$ 22,733
TOTAL CURRENT ASSETS	3,343	22,733
Office		9,414
Computer	1,712	12,506
	1,712	21,920
Less: Accumulated depreciation	(143)	(21,920)
Total equipment	1,569
OTHER ASSETS	6,230	4,147
TOTAL ASSETS	11,142	26,880
CURRENT LIABILITIES
Bridge Loan Payable - Stockholder and accrued interest	399,103	0
Accounts payable and accrued expenses	276,532	145,733
Income taxes payable	2,723	2,500
TOTAL CURRENT LIABILITIES	678,358	148,233
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Common stock at $.001 par value, 20,000,000 shares authorized; 7,613,338 shares issued and 6,613,338 outstanding for December 31, 2015 and 2014	7,613	7,613
Additional paid-in-capital	5,880,119	5,401,490
Accumulated deficit	(6,306,297)	(5,282,875)
Treasury stock, at cost $.001 par value, 1,000,000 shares, for December 31, 2015 and 2014	(100,000)	(100,000)
Accumulated other comprehensive loss	(148,651)	(147,581)
TOTAL STOCKHOLDERS' DEFICIT	(667,216)	(121,353)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 11,142	$ 26,880

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014	Jul. 27, 2016	Jun. 27, 2016	Jun. 26, 2016	Feb. 12, 2016	Oct. 02, 2015	Oct. 01, 2015
Common Stock, Par Value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.001	$ 0.0001	$ 0.0001	$ 0.000001	$ 0.0001	$ 0.001
Common Stock, Shares Authorized (in shares)	100,000,000	20,000,000	20,000,000	100,000,000	100,000,000	100,000,000,000		20,000,000	10,000,000
Common Stock, Shares Issued (in shares)	8,307,915	7,612,838	7,613,338
Common Stock, Shares Outstanding (in shares)	8,307,915	6,612,838	6,613,338
Treasury Stock, Par Value	$ 0.001	$ 0.001	$ 0.001
Treasury Stock, Shares (in shares)	1,000,000	1,000,000	1,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
REVENUE	$ 0	$ 0
OPERATING AND ADMINISTRATIVE EXPENSES
Sponsorship research and development	170,575	67,270
Legal fees	164,855	25,287
Salaries	73,815	88,791
Patent expense	22,435	60,434
Consulting	10,008	10,861
Payroll taxes and employee benefits	10,170	5,335
Rent - related party and officer	4,546	5,862
Travel	6,228	2,892
Telephone, internet and website	1,658	2,703
Miscellaneous	165
Rebates from research and development Canadian tax credits	(8,181)	(78,366)
Total research and development expenses	456,274	191,069
General and administrative expenses	568,764	101,031
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES	1,025,038	292,100
LOSS FROM OPERATIONS	(1,025,038)	(292,100)
OTHER INCOME (EXPENSE)
Interest income		49
Interest expense - stockholder	(11,473)
Foreign currency exchange gain (loss)	13,089	(10,430)
TOTAL OTHER INCOME (EXPENSE)	1,616	(10,381)
NET LOSS	(1,023,422)	(302,481)
COMPREHENSIVE LOSS
Foreign exchange translation loss	(1,070)	(156,338)
TOTAL COMPREHENSIVE LOSS	$ (1,024,492)	$ (458,819)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.15)	$ (0.05)
Weighted average common shares - basic and diluted (in shares)	6,613,338	6,613,338

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Preferred Stock [Member]Preferred Class A [Member]	AOCI Attributable to Parent [Member]	Total
BALANCE (in shares) at Dec. 31, 2013	7,613,338			(1,000,000)
BALANCE at Dec. 31, 2013	$ 7,613	$ 5,316,322	$ (4,980,394)	$ (100,000)	$ 8,757	$ 252,298
Stock compensation - stock options		85,168				85,168
Foreign currency translation loss					(156,338)	(156,338)
Net Income (Loss) Attributable to Parent			(302,481)			(302,481)
BALANCE (in shares) at Dec. 31, 2014	7,613,338			(1,000,000)
BALANCE at Dec. 31, 2014	$ 7,613	5,401,490	(5,282,875)	$ (100,000)	(147,581)	(121,353)
Stock compensation - stock options		478,629				478,629
Foreign currency translation loss					(1,070)	(1,070)
Net Income (Loss) Attributable to Parent			(1,023,422)			(1,023,422)
BALANCE (in shares) at Dec. 31, 2015	7,612,838			(1,000,000)
BALANCE at Dec. 31, 2015	$ 761	5,886,971	(6,306,297)	$ (100,000)	(148,651)	(667,216)
Stock compensation - stock options		450,566				450,566
Net Income (Loss) Attributable to Parent			(1,719,749)			(1,719,749)
BALANCE (in shares) at Sep. 30, 2016	8,307,915
BALANCE at Sep. 30, 2016	$ 831	$ 11,137,911	$ (8,026,046)		$ (174,108)	$ 2,938,591

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net Loss	$ (1,023,422)	$ (302,481)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	143	380
Stock based compensation	478,629	85,168
Interest added to bridge loan	11,473
Changes in operating assets and liabilities
Prepaid research and development expenses		47,224
Other assets	(2,916)	(1,084)
Accounts payable and accrued expenses	154,529	15,423
Income taxes payable	223	(600)
NET CASH USED IN OPERATING ACTIVITIES	(381,341)	(155,970)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of equipment	(1,791)
NET CASH USED IN INVESTING ACTIVITIES	(1,791)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from bridge loan	387,630
NET CASH PROVIDED BY FINANCING ACTIVITIES	387,630
Effect of exchange rate on cash and cash quivalents	(23,888)	22,720
NET DECREASE IN CASH AND CASH EQUIVALENTS	(19,390)	(133,250)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	22,733	155,983
CASH AND CASH EQUIVALENTS, END OF YEAR	3,343	22,733
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest expense
Cash paid for income taxes

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Business	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1 ORGANIZATION AND NATURE OF BUSINESS Company Background Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”) was originally incorporated in Delaware on February 3, 1994 February 1994, For the next 10 February 6, 2004, 11 That same year, a biotechnology company called Protagenic Therapeutics, Inc. (referred to herein as “Prior Protagenic”) was organized on September 29, 2004 September 14, 2015, August 7, 2015. Protagenic Therapeutics Canada (2006) 2006 7 On January 31, 2007, March 2005 May 2, 2007, As part of a corporate re-branding strategy, on June 25, 2009, The Reverse Business Combination (Merger) On February 12, 2016 June 17, 2016, On the Closing Date, all of the issued and outstanding (6,612,838) 1 1 $0.000001 1 1 1,807,744 $0.87 3,403,367 $1.03 The common stockholders of Atrinsic, Inc. before the Merger (“Predecessor”) retained 25,867 $0.0001 297,468 17,784 $1.25 295,945 $1.25 $665,000 $35,000 The Merger is being accounted for as a “Reverse Business Combination,” and Prior Protagenic is deemed to be the accounting acquirer in the merger. Consequently, the assets and liabilities and the historical operations that will be reflected in the financial statements prior to the Merger will be those of Prior Protagenic, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of Prior Protagenic, historical operations of Prior Protagenic and combined operations of Prior Protagenic, Predecessor and the Company from the Closing Date of the Merger. Further, as a result of the issuance of the shares of Series B Preferred Stock pursuant to the Merger, a change in control of the Company occurred as of the date of consummation of the Merger. The Merger will be treated as a recapitalization of the Company for financial accounting purposes. The historical financial statements of Predecessor before the Merger will be replaced with the historical financial statements of Prior Protagenic before the Merger in all future filings with the Securities and Exchange Commission (the “SEC”). At the closing of the Merger, Predecessor had a 51% 49% 51% Immediately after the closing of the Merger, the Company also split off all of its equity interest in 29 The Private Offering Concurrently and a condition of the closing of the Merger, we conducted the first first 2,775,000 $1.25 $3,468,750. $350,000 $150,000 March 2, 2016, second 913,200 $1,141,500. April 15, 2016 420,260 $525,325. $159,183 $15,000 $266,727 127,346 $146,641 $1.25 three 4,108,460 $4,635,575 $4,283,438 $5,135,575 $4,783,438, $350,000 $150,000 Debt Exchange Simultaneous with the Merger and the Private Offering, holders of $665,000 $35,000 295,945 $1.25 $340,784 6). The Reverse Split Our stockholders voted at a special meeting held on June 17, 2016 1 15,463.7183 1 1 9.99% July 27, 2016, 10,146,000 11,018,766 10,146,000 872,766 one September 30, 2016, 8,221,837 8,221,837 (1,924,163) fourth 2016 Also at this time, the total number of stock which the Company is authorized to issue will be 120,000,000, 100,000,000 $0.0001 20,000,000 $0.000001	NOTE 1 Protagenic Therapeutics, Inc. (“PTI U.S.A.”) was organized on September 29, 2004 September 14, 2015, August 7, 2015. Protagenic Therapeutics Canada (2006) 2006

Note 2 - Liquidity

Note 2 - Liquidity	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Liquidity and Going Concern [Text Block]	NOTE 2 - LIQUIDITY As shown in the accompanying condensed consolidated financial statements, the Company incurred a net loss of $1,719,749 $586,387 nine September 30, 2016 2015, $455,476 $439,477 three September 30, 2016 2015, $8,026,046 September 30, 2016. three nine $2,937,320 September 30, 2016 eighteen 2018.	NOTE 2 As shown in the accompanying consolidated financial statements, the Company incurred a net loss of $1,023,422 $302,481 December 31, 2015 2014, $6,306,297 December 31, 2015, $675,015 December 31, 2015. The Company intends to finance its activities through managing current cash and cash equivalents on hand and seeking additional funds raised in the future through the issuance of common stock, borrowing of funds or merging with another company (see Note 11). February 2016 April 2016, $4,635,575 $4,283,438) 2017. 12 $2,691,000.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3 SUMMARY OF SIGNFICANT ACCOUNTING POLICIES Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the SEC for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2016 2015. The condensed consolidated financial statements include the accounts of Atrinsic, Inc., and its wholly owned subsidiary, Protagenic Acquisition Corp, and Protagenic Therapeutics, Inc., which was merged with and into Protagenic Acquisition Corp, on February 12, 2016, The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2015, December 31, 2015 2014 8 July 12, 2016. three nine September 30, 2016 December 31, 2016 Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include the allocation of the fair value of acquired assets and liabilities associated with the Merger, assessment of intangible assets, including goodwill and income tax provisions and allowances. The Company also relies on estimates for the valuation of stock-based compensation expense and financial instruments. Goodwill and indefinite-lived assets Goodwill and indefinite-lived assets are not amortized, but are evaluated for impairment annually or when indicators of a potential impairment are present. Our impairment testing of goodwill is performed separately from our impairment testing of indefinite-lived intangibles. The annual evaluation for impairment of goodwill and indefinite-lived intangibles is based on valuation models that incorporate assumptions and internal projections of expected future cash flows and operating plans. On the date of the Merger, the Company recorded the fair value of shares given to Predeccesor stockholders as Goodwill, and subsequent to the merger the Company determined that goodwill was impaired and wrote it down to zero. The allocation of the consideration transferred is as follows: Allocated to: Atrinsic 25,867 shares Common stock $ 32,334 Atrinsic Series A preferred stock as converted to Series B preferred stock, 297,468 shares 371,835 Total value of shares issued to Atrinsic on Merger date 404,169 Goodwill 404,169 Net value of consideration $ 0 Fair Value Measurements Accounting Standards Codification 820, 820”) 820 three 1) 3). The three Level 1 Level 2 Level 3 Cash equivalents consisting of money market funds are carried at cost which approximate fair value due to its short-term nature. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value as of September 30, 2016. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrant liabilities $ 516,757 $ — $ — $ 516,757 $ 516,757 The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) nine September 30, 2016: Fair Value Measurement Using Level 3 Inputs Total Balance, December 31, 2015 $ — Issuance of derivative warrants liabilities 487,425 Change in fair value of derivative warrant liabilities 29,332 Balance, September 30, 2016 $ 516,757 The fair value of the derivative feature of the 127,346 295,945 February 12 , 201 6 September 30 , 201 6 Risk free interest rate 1.20 % 1.14 % Dividend yield 0.00 % 0.00 % Expected volatility 156 % 213 % Contractual term (in years) 5.0 4.25 Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar term on the date of the grant. Dividend yield: The Company uses a 0% Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term. Remaining term: The Company’s remaining term is based on the remaining contractual maturity of the warrants. During the nine September 30, 2016, $29,332 Impairment The Company estimates the expected undiscounted future cash flows and operating plans and compares such amounts to the carrying amount of the goodwill to determine if the carrying amount is recoverable. If the carrying amount exceeds the estimated undiscounted future cash flows, the Company will adjust the carrying amount of the goodwill to the fair value. The factors used to determine fair value are subject to management’s judgement and expertise and include, but are not limited to, recent sales prices of comparable companies, the present value of future cash flows, anticipated capital expenditures and various discount rates commensurate with the risk and current market conditions associated with realizing the expected cash flows projected. These assumptions represent Level 3 nine September 30, 2016 $404,169. Derivative Liability The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with paragraph 815 10 05 4 815 40 25 The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 The Company utilizes a Black-Scholes option pricing model to compute the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The Company determined the fair value of the binomial lattice model and the Black-Scholes valuation model to be materially the same. The Company records the change in the fair value of the derivative as other income or expense in the consolidated statements of operations. Revenue Recognition The Company has not begun planned principal operations and has not generated any revenue since inception. Stock-Based Compensation Expenses The Company accounts for stock based compensation costs under the provisions of ASC No. 718, 718. 718 Stock-Based Compensation for Non-Employees The Company accounts for warrants and options issued to non-employees under ASC 505 50, Equity – Equity Based Payments to Non-Employees, Basic and Diluted Net (Loss) per Common Share Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. For the nine September 30, 2016 2015, 6,418,887 4,801,112, nine September 30, 2016 2015, 2,796,929 0, Potentially Outstanding Dilutive Common Shares For the Nine Months Ended September 30, 2016 For the Nine Months Ended September 30, 2015 Conversion Feature Shares Common shares issuable under the conversion feature of preferred shares 2,796,929 - Stock Option Shares 2,592,229 1,647,745 Warrant Shares 3,826,658 3,153,367 Total potentially outstanding dilutive common shares 9,215,816 4,801,112 Recent accounting pronouncements In November 2015, 2015 17, 740). 2015 17 December 15, 2016. On March 30, 2016, 2016 09, December 15, 2016, In February 2016, 2016 02, 2016 02 2016 02 December 15, 2018, In August 2016, 2016 15, “Statement of Cash Flows (Topic 230): 2016 15”). 2016 15 eight 2016 15 December 15, 2017. 2016 15 Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.	NOTE 3 Basis of Presentation The consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of PTI U.S.A, and its wholly owned subsidiary, PTI Canada. All significant intercompany transactions and balances have been eliminated from the consolidated financial statements. PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2015 AND 2014 NOTE 3 Foreign Currency Translation and Transactions The assets and liabilities of the Company’s foreign subsidiary PTI Canada are translated into U.S. dollars from its functional currency using the exchange rate in effect at the balance sheets date. Additionally, the accounts on the statements of operations are translated using exchange rates approximating average rates prevailing during the years. Equity accounts are translated at historical exchange rates. Translation adjustments that arise from translating its financial statements from the local currency to the U.S. dollar are accumulated and reflected as a separate component of stockholders’ deficit. The current year effect of the transaction adjustments are included on the statement of operations as a foreign currency exchange gain (loss). Use of Estimates In preparing consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amount of revenues and expenses during the reporting period. Significant estimates include accruals, contingencies, valuation allowance for deferred tax assets and valuation of stock options and warrants. These estimates may Cash and Cash Equivalents Cash equivalents consist of money market instruments with an original maturity at the time of purchase of three two one may Equipment Equipment was stated at cost less accumulated depreciation. Improvements and replacements of equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of equipment are charged to expense as incurred. When assets are retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss will be reported in the consolidated statements of operations. Depreciation is computed using straight- line methods over their estimated useful lives ranging from 3 5 PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2015 AND 2014 NOTE 3 OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) Rebates from Research and Development Credits The Company derives rebates from scientific research and experimental development tax credits issued by the Canada Revenue Agency for qualified expenditures. The credits are recognized when the rebate is issued. The amounts received are reinvested into the Company’s scientific research, experimental development and operational works conducted in Canada. Research and Development Expenses, net of Rebates The Company’s research and development expenditures for present and future products are expensed as incurred. Treasury Stock Management of the Company does not plan to retire the stock and applies the cost method to its treasury stock transactions. Differences between proceeds for reissuance of treasury stock and the cost are credited or charged to additional paid in capital to the extent of the prior credits and thereafter to accumulated deficit. Fair Value Measurements Accounting Standards Codification 820, 820”) 820 three 1) 3). The three Level 1 Level 2 Level 3 There were no transfers in or out of any level for the years ended December 31, 2015 2014. Cash and cash equivalents, accounts payable, and accrued expenses carry value equals approximately the fair value due to its short term nature. Based on the borrowing rates currently available to the Company for loans with similar terms and the expected short term maturity, the carrying value of the bridge note payable approximates fair value. PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2015 AND 2014 NOTE 3 OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) Stock-Based Compensation The Company accounts for stock based compensation costs under the provisions of ASC No. 718, Compensation—Stock Compensation 718. 718 718 Income Taxes The Company accounts for income taxes utilizing the liability method. Deferred income tax assets and liabilities are computed annually for differences between the consolidated financial statement basis and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such asset will be realized. Management has determined that a valuation allowance is required for the deferred tax assets which is primarily attributable to net operating loss carry forwards for federal and state tax purposes. The net operating losses expire through 2035 2022 Basic and Diluted Net (Loss) per Common Share Basic (loss) per common share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially dilutive securities consisting of options and warrants aggregating 5,111,111 4,371,111 December 31, 2015 2014, . PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2015 AND 2014 NOTE 3 Recent Accounting Pronouncements On March 30, 2016, 2016 09, December 15, 2016, In February 2016, 2016 02, Leases 2016 02 2016 02 December 15, 2018, In November 2015, 2015 17, Income taxes. 2015 17 December 15, 2016, In August 2014, 2014 15, 2014 15 (1) (2) (3) (4) (5) (6) one December 15, 2016, Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.

Note 4 - Accounts Payable and A

Note 4 - Accounts Payable and Accrued Expenses	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 4 ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of the following at: September 30, 2016 December 31, 2015 Legal $ 10,723 $ 186,936 Salaries - 41,166 Patent expense 31,315 29,239 Research and development 67,560 8,128 Payroll taxes and employee benefits - 6,222 Other 21,113 7,564 Accounting and tax expenses 857 - $ 131,568 $ 279,255	NOTE 4 Accounts payable and accrued expenses consist of the following as of December 31: 201 5 201 4 Legal expenses $ 186,936 $ 51,120 Salaries 41,166 -- Patent cost 29,239 87,244 Research and development 8,128 6,089 Payroll taxes and employee benefits 6,222 -- Other 4,841 1,280 $ 276,532 $ 145,733

Note 5 - Bridge Loan Payable -

Note 5 - Bridge Loan Payable - Stockholder	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 5 During January 1, 2015 February 12, 2016, $422,752 $1.25 10% $7,905 $0 nine September 30, 2016 2015, February 12, 2016, $350,000 $1.25 June 17, 2016, $75,265 $1.25	NOTE 5 The Company did not 2014. January 1, 2015 December 31, 2015, $399,103 $1.25 10% $11,473 December 31, 2015. December 31, 2015, $350,000 $1.25 June 2016, $1.25

Note 6 - Derivative Liabilities

Note 6 - Derivative Liabilities	9 Months Ended
	Sep. 30, 2016
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 6 Upon closing of the private placement transactions on February 12, 2016, 127,346 295,945 $1.25 five

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Deficit)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7 STOCKHOLDERS’ EQUITY (DEFICIT) On June 17, 2016, third July 27, 2016 one 15,463.7183 15,463.7183 one 100 100 $0.000001 $0.0001 5 20 Stock-Based Compensation In connection with the Merger, all of the issued and outstanding options to purchase shares of Prior Protagenic common stock converted, on a 1 1 New Options 2006 2006 The Plan is authorized to issue up to 2,000,000 one five ten There were 2,592,229 September 30, 2016. Expected dividend yield 0% Risk free interest rate 1.01% - 2.43% Expected life in years 5 Expected volatility 85% - 213% The following is an analysis of the stock option grant activity under the Plan: Exercise Weighted Average Number Price Exercise Price Stock Options Outstanding January 1, 2016 1,707,744 $ 0.84 Granted 1,301,084 $ 1.25 Expired (416,599 ) Outstanding September 30, 2016 2,592,229 $ 1.04 On February 12, 2016, 100,000 2006 $1.25 ten three 35 0.18 2,778 $10,383 $5,192 nine three September 30, 2016 March 31, 2016, On April 15, 2016, 40,000 5,000 10 24 $1.25 175,000 On April 15, 2016, 1,008,299 10 12 48 $1.25 During the quarter, 17,785 3 $1.25 The total number of options granted and vested during the nine September 30, 2016 1,974,445 133,229, 1,974,445 $1.25 The Company recognized compensation expense related to options issued of $450,566 nine September 30, 2016. On June 17, 2016, 2016 2006 8 June 20, 2016. Warrants: In connection with the Merger, all of the issued and outstanding warrants to purchase shares of Prior Protagenic common stock, converted, on a 1 1 New Warrants Simultaneous with the Merger and the Private Offering, New Warrants to purchase 3,403,367 $1.05 $665,000 $35,000 five 295,945 $1.25 127,346 $1.25 423,291 6. A summary of warrant issuances are as follows: Exercise Weighted Average Number Price Exercise Price Warrants Outstanding January 1, 2016 3,403,367 $ 1.05 Granted 423,291 $ 1.25 Outstanding September 30, 2016 3,826,658 $ 1.07	NOTE 6 Common Stock The Company adopted a certificate of amendment to the Company’s restated certificate of incorporation to increase the number of authorized shares of its $.001 10,000,000 20,000,000 October 2, 2015. No December 31, 2015 2014. Stock-Based Compensation On March 15, 2006, 2006 140,000 April 1, 2012, 2,000,000 one five ten December 31, 2015 2014, 490,000 240,000 $1.25 $1.00 2015 2014 six five one Management has determined that for each round of stock options granted, it was reasonable to estimate the fair value of the common stock options using the Black Scholes option pricing model. Accordingly, the Company has accounted for options using this calculated value method. Based on the fact that the Company is a privately held company with no revenue, management has estimated its expected future equity volatility factor in valuing the Company’s common stock equivalents by starting with its historical volatility adjusted for the volatility of equity interests from comparable publicly traded and privately held published companies to arrive at such industry benchmarks to evaluate. The fair value of each stock option granted and warrant issued during 2015 2014 2015 2014 Expected dividend yield 0% 0 % Risk free interest rate 1.66% - 2.43% 2.30 % Expected life in years 10 10 Expected volatility 85% 85 % No December 31, 2015 2014. December 31, 2015, no $190,751 $85,168 December 31, 2015 2014, Stock-Based Compensation (continued) As of December 31, 2015 2014, 292,256 782,256, December 31, 2015 $290,985, The following is an analysis of the stock option grant activity under the Plan: Exercise Weighted Average Number Price Exercise Price Stock Options Outstanding January 1, 2014 977,744 $ 0.60 Granted 240,000 $ 1.00 Outstanding December, 31, 2014 1,217,744 $ 0.68 Granted 490,000 $ 1.25 Outstanding December, 31, 2015 1,707,744 $ 0.84 The following is an analysis of the vested and non-vested stock options under the Plan as of December 31, 2015: Number of Options Expiration Date Remaining Contractual Life (Years) Exercise Price 104,150 March 1, 2016 0.17 $ 0.26 312,449 March 15, 2016 0.21 $ 0.26 55,000 August 1, 2016 0.59 $ 0.26 60,000 November 1, 2016 0.84 $ 0.26 21,145 February 1, 2017 1.09 $ 1.00 290,000 March 1, 2021 5.25 $ 1.00 10,000 June 10, 2021 5.45 $ 1.00 50,000 April 1, 2022 6.25 $ 1.00 75,000 December 1, 2022 6.92 $ 1.00 90,000 March 1, 2024 8.17 $ 1.00 215,000 March 1, 2025 9.17 $ 1.25 75,000 March 9, 2025 9.19 $ 1.25 150,000 March 1, 2027 11.17 $ 1.00 200,000 January 22, 2030 14.07 $ 1.25 1,707,744 Warrants The Company has conducted private placement offerings to raise financing since its formation. In connection with the private placement offerings that occurred in 2013, 2011, 2007, $1.00 $0.001 3 $1.00 ten The Company has warrants outstanding as follows: December 31, 2015 December 31, 2014 Financing and stock subscriptions (includes 300,000 warrants to the Major Stockholder and Chairman) 2,100,000 2,100,000 Consultants 350,000 100,000 Major Stockholder and Chairman 953,367 953,367 Total Warrants Issued 3,403,367 3,153,367 A summary of warrant issuances are as follows: Exercise Weighted Average Number Price Exercise Price Warrants Outstanding January 1, 2014 3,153,367 $ 1.01 Granted - $ - Outstanding December, 31, 2014 3,153,367 $ 1.00 Granted 250,000 $ 1.25 Outstanding December, 31, 2015 3,403,367 $ 1.05 All outstanding warrants are currently exercisable. A summary of warrants issued and outstanding at December 31, 2015 Number of Common Stock Equivalents Expiration Date Remaining Contractual Life(Years) Exercise Price 100,000 01/01/2017 1.2 $ 1.25 675,000 07/07/2021 5.5 to 6.7 $ 1.00 2,628,367 12/20/2023 7.3 to 8.1 $ 1.05 3,403,367 The Company recognized stock-based compensation expense pertaining to the warrants issued of $287,878 $0 December 31, 2015 2014, As of December 31, 2015, 1,253,367 417,789 $1.00 10 May 19, 2021 100,000 February18, 2023 317,789

Note 8 - Collaborative Agreemen

Note 8 - Collaborative Agreements	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
In Process Research and Development [Member]
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 8 COLLABORATIVE AGREEMENTS The Company and the University of Toronto, a stockholder of the Company (the “University”) entered into an agreement effective December 14, 2004 March 31, 2013. The Company and the University entered into an agreement effective April 1, 2014 March 30, 2015. September 2015, September 30, 2016 Prior to January 1, 2016 25,000 $1.00 10 April 1, 2022. September 30, 2016 275,000 125,000 $1.00 10 13 March 30, 2021 March 1, 2027. The sponsorship research and development expenses pertaining to the Research Agreements were $3,000 $7,056 three September 30, 2016 2015, $4,500 $10,584 nine September 30, 2016,	NOTE 8 The Company and the University of Toronto, a stockholder of the Company (the “University”) entered into an agreement effective December 14, 2004 March 31, 2013. The Company and the University entered into an agreement effective April 1, 2014 March 31, 2015. September 2015, March 31, 2016 As of December 31, 2015 129,000 $.26 $1.00 10 March 15, 2016 April 1, 2022. December 31, 2015 483,299 62,500 $0.26 $1.00 10 13 March 15, 2016 March 1, 2027. The sponsorship research and development expenses were $170,575 $67,270 December 31, 2015 2014,

Note 9 - Licensing Agreements

Note 9 - Licensing Agreements	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Licensing Agreements [Member]
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 9 LICENSING AGREEMENTS On July 31, 2005, February 18, 2015 Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% 10% September 9, 2006, 2.5% no nine September 30, 2016 2015 In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may 3% may may may 2.5% The patent applications were made in the name of the Professor and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the six	NOTE 9 On July 31, 2005, February 18, 2015 Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% 10% September 9, 2006, 2.5% no December 31, 2015 2014 In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may 3% may may may 2.5% The Company has incurred legal expense for research and development projects associated with the License Agreement and its amendment of $0 $25,287 December 31, 2015 2014, The Company also incurred patent costs for research and development projects associated with the License Agreement and its amendment of $22,435 60,434 December 31, 2015 2014, The patent applications were made in the name of the Professor and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the six

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 10 Consulting Agreement The Company had an employment agreement with its Officer/Related Party which expired on December 31, 2015. $6,489 December 31, 2015, 75,000 $64,223 $53,519 2015. As the agreement above expired, the Company issued a consulting agreement in its place that extended the majority of the terms of the employment agreement on a month-to-month basis. As a consultant, he is responsible for financial reporting, data compilation, and document retrieval services, reporting to the Chief Financial Officer, and to endeavor to secure non-dilutive grant funding for the Company. Prior to January 1, 2016, 250,000 $0.26, $1.00, $1.25 10 August 1, 2016 March 9, 2025. $2,000 2016 may fifteen (15) The Company has accrued $20,600 nine September 30, 2016 $0 three nine September 30, 2015. Consulting Agreement PTI Canada entered into a consulting agreement with a stockholder of the Company (the “Consultant”) which expired on December 31, 2015, December 31, 2016 January 1, 2016, 150,000 $1.00 $1.25 10 March 30, 2021 March 1, 2025. CA$3,000 may fifteen (15) The Company has accrued $18,122 three September 30, 2016 $1,619 three September 30, 2015. $67,161 nine September 30, 2016 $1,619 nine September 30, 2015. Legal Proceedings From time to time we may	NOTE 10 CONTINGENCIES Operating Lease with Related Party The Company paid its sole employee and officer, a related party, serving as the interim president and chief operating officer of PTI U.S.A. and a director and president and chief operating officer of PTI Canada (the “Officer/Related Party”), rent on the property which the Company is renting. The Company occupies roughly 1/3 1/3 December 31, 2015, $430 As of January 1, 2016 Employment Agreement The Company had an employment agreement with its sole employee the Officer/Related Party which expired on December 31, 2015. $6,489 December 31, 2015, 75,000 $64,223 $53,519 2015. Consulting Agreement PTI Canada entered into a consulting agreement with a stockholder of the Company, (the “Consultant”) which expired on December 31, 2015 December 31, 2015, 100,000 4,167 $1.00 10 March 30, 2021 March 1, 2024. $42,816 $35,680 2015. CA$1,000 may i.e. fifteen (15) The Company paid the Consultant $10,861 $11,650 December 31, 2015 2014, Legal Proceedings From time to time we may

Note 11 - Subsequent Events

Note 11 - Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 11 SUBSEQUENT EVENTS The Company has evaluated the period after the balance sheet date up through the date that the condensed consolidated financial statements were filed, and determined that other than noted above, there were subsequent events or transactions that required recognition or disclosure in the condensed consolidated financial statements. At the October 26, 2016 one 25,000 $1.25 48 100,000 one 3 January 2017 January 2020.	NOTE 11 On February 12, 2016, Acquisition Corp. Atrinsic Merger Simultaneously with the Merger, on February 12, 2016, 1 1 $0.000001 Series B Preferred Stock February 12, 2016, 1 1 2006 February 12, 2016, one one 15,463.7183 Concurrently with the closing of the Merger, we conducted the first first 2,775,000 $1.25 $3,468,750. $350,000 $150,000 March 2, 2016 second 913,200 $1,141,500. April 15, 2016 420,260 $525,325. For all three $4,635,575 $4,283,438 $5,135,575 $4,783,438, $500,000 4,108,460 $159,183 $15,000 127,346 $1.25

Note 1 - Organization and Nat23

Note 1 - Organization and Nature of Business	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1 ORGANIZATION AND NATURE OF BUSINESS Company Background Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”) was originally incorporated in Delaware on February 3, 1994 February 1994, For the next 10 February 6, 2004, 11 That same year, a biotechnology company called Protagenic Therapeutics, Inc. (referred to herein as “Prior Protagenic”) was organized on September 29, 2004 September 14, 2015, August 7, 2015. Protagenic Therapeutics Canada (2006) 2006 7 On January 31, 2007, March 2005 May 2, 2007, As part of a corporate re-branding strategy, on June 25, 2009, The Reverse Business Combination (Merger) On February 12, 2016 June 17, 2016, On the Closing Date, all of the issued and outstanding (6,612,838) 1 1 $0.000001 1 1 1,807,744 $0.87 3,403,367 $1.03 The common stockholders of Atrinsic, Inc. before the Merger (“Predecessor”) retained 25,867 $0.0001 297,468 17,784 $1.25 295,945 $1.25 $665,000 $35,000 The Merger is being accounted for as a “Reverse Business Combination,” and Prior Protagenic is deemed to be the accounting acquirer in the merger. Consequently, the assets and liabilities and the historical operations that will be reflected in the financial statements prior to the Merger will be those of Prior Protagenic, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of Prior Protagenic, historical operations of Prior Protagenic and combined operations of Prior Protagenic, Predecessor and the Company from the Closing Date of the Merger. Further, as a result of the issuance of the shares of Series B Preferred Stock pursuant to the Merger, a change in control of the Company occurred as of the date of consummation of the Merger. The Merger will be treated as a recapitalization of the Company for financial accounting purposes. The historical financial statements of Predecessor before the Merger will be replaced with the historical financial statements of Prior Protagenic before the Merger in all future filings with the Securities and Exchange Commission (the “SEC”). At the closing of the Merger, Predecessor had a 51% 49% 51% Immediately after the closing of the Merger, the Company also split off all of its equity interest in 29 The Private Offering Concurrently and a condition of the closing of the Merger, we conducted the first first 2,775,000 $1.25 $3,468,750. $350,000 $150,000 March 2, 2016, second 913,200 $1,141,500. April 15, 2016 420,260 $525,325. $159,183 $15,000 $266,727 127,346 $146,641 $1.25 three 4,108,460 $4,635,575 $4,283,438 $5,135,575 $4,783,438, $350,000 $150,000 Debt Exchange Simultaneous with the Merger and the Private Offering, holders of $665,000 $35,000 295,945 $1.25 $340,784 6). The Reverse Split Our stockholders voted at a special meeting held on June 17, 2016 1 15,463.7183 1 1 9.99% July 27, 2016, 10,146,000 11,018,766 10,146,000 872,766 one September 30, 2016, 8,221,837 8,221,837 (1,924,163) fourth 2016 Also at this time, the total number of stock which the Company is authorized to issue will be 120,000,000, 100,000,000 $0.0001 20,000,000 $0.000001	NOTE 1 Protagenic Therapeutics, Inc. (“PTI U.S.A.”) was organized on September 29, 2004 September 14, 2015, August 7, 2015. Protagenic Therapeutics Canada (2006) 2006

Note 2 - Liquidity24

Note 2 - Liquidity	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Liquidity and Going Concern [Text Block]	NOTE 2 - LIQUIDITY As shown in the accompanying condensed consolidated financial statements, the Company incurred a net loss of $1,719,749 $586,387 nine September 30, 2016 2015, $455,476 $439,477 three September 30, 2016 2015, $8,026,046 September 30, 2016. three nine $2,937,320 September 30, 2016 eighteen 2018.	NOTE 2 As shown in the accompanying consolidated financial statements, the Company incurred a net loss of $1,023,422 $302,481 December 31, 2015 2014, $6,306,297 December 31, 2015, $675,015 December 31, 2015. The Company intends to finance its activities through managing current cash and cash equivalents on hand and seeking additional funds raised in the future through the issuance of common stock, borrowing of funds or merging with another company (see Note 11). February 2016 April 2016, $4,635,575 $4,283,438) 2017. 12 $2,691,000.

Note 3 - Summary of Significa25

Note 3 - Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3 SUMMARY OF SIGNFICANT ACCOUNTING POLICIES Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the SEC for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2016 2015. The condensed consolidated financial statements include the accounts of Atrinsic, Inc., and its wholly owned subsidiary, Protagenic Acquisition Corp, and Protagenic Therapeutics, Inc., which was merged with and into Protagenic Acquisition Corp, on February 12, 2016, The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2015, December 31, 2015 2014 8 July 12, 2016. three nine September 30, 2016 December 31, 2016 Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include the allocation of the fair value of acquired assets and liabilities associated with the Merger, assessment of intangible assets, including goodwill and income tax provisions and allowances. The Company also relies on estimates for the valuation of stock-based compensation expense and financial instruments. Goodwill and indefinite-lived assets Goodwill and indefinite-lived assets are not amortized, but are evaluated for impairment annually or when indicators of a potential impairment are present. Our impairment testing of goodwill is performed separately from our impairment testing of indefinite-lived intangibles. The annual evaluation for impairment of goodwill and indefinite-lived intangibles is based on valuation models that incorporate assumptions and internal projections of expected future cash flows and operating plans. On the date of the Merger, the Company recorded the fair value of shares given to Predeccesor stockholders as Goodwill, and subsequent to the merger the Company determined that goodwill was impaired and wrote it down to zero. The allocation of the consideration transferred is as follows: Allocated to: Atrinsic 25,867 shares Common stock $ 32,334 Atrinsic Series A preferred stock as converted to Series B preferred stock, 297,468 shares 371,835 Total value of shares issued to Atrinsic on Merger date 404,169 Goodwill 404,169 Net value of consideration $ 0 Fair Value Measurements Accounting Standards Codification 820, 820”) 820 three 1) 3). The three Level 1 Level 2 Level 3 Cash equivalents consisting of money market funds are carried at cost which approximate fair value due to its short-term nature. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value as of September 30, 2016. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrant liabilities $ 516,757 $ — $ — $ 516,757 $ 516,757 The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) nine September 30, 2016: Fair Value Measurement Using Level 3 Inputs Total Balance, December 31, 2015 $ — Issuance of derivative warrants liabilities 487,425 Change in fair value of derivative warrant liabilities 29,332 Balance, September 30, 2016 $ 516,757 The fair value of the derivative feature of the 127,346 295,945 February 12 , 201 6 September 30 , 201 6 Risk free interest rate 1.20 % 1.14 % Dividend yield 0.00 % 0.00 % Expected volatility 156 % 213 % Contractual term (in years) 5.0 4.25 Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar term on the date of the grant. Dividend yield: The Company uses a 0% Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term. Remaining term: The Company’s remaining term is based on the remaining contractual maturity of the warrants. During the nine September 30, 2016, $29,332 Impairment The Company estimates the expected undiscounted future cash flows and operating plans and compares such amounts to the carrying amount of the goodwill to determine if the carrying amount is recoverable. If the carrying amount exceeds the estimated undiscounted future cash flows, the Company will adjust the carrying amount of the goodwill to the fair value. The factors used to determine fair value are subject to management’s judgement and expertise and include, but are not limited to, recent sales prices of comparable companies, the present value of future cash flows, anticipated capital expenditures and various discount rates commensurate with the risk and current market conditions associated with realizing the expected cash flows projected. These assumptions represent Level 3 nine September 30, 2016 $404,169. Derivative Liability The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with paragraph 815 10 05 4 815 40 25 The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 The Company utilizes a Black-Scholes option pricing model to compute the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The Company determined the fair value of the binomial lattice model and the Black-Scholes valuation model to be materially the same. The Company records the change in the fair value of the derivative as other income or expense in the consolidated statements of operations. Revenue Recognition The Company has not begun planned principal operations and has not generated any revenue since inception. Stock-Based Compensation Expenses The Company accounts for stock based compensation costs under the provisions of ASC No. 718, 718. 718 Stock-Based Compensation for Non-Employees The Company accounts for warrants and options issued to non-employees under ASC 505 50, Equity – Equity Based Payments to Non-Employees, Basic and Diluted Net (Loss) per Common Share Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. For the nine September 30, 2016 2015, 6,418,887 4,801,112, nine September 30, 2016 2015, 2,796,929 0, Potentially Outstanding Dilutive Common Shares For the Nine Months Ended September 30, 2016 For the Nine Months Ended September 30, 2015 Conversion Feature Shares Common shares issuable under the conversion feature of preferred shares 2,796,929 - Stock Option Shares 2,592,229 1,647,745 Warrant Shares 3,826,658 3,153,367 Total potentially outstanding dilutive common shares 9,215,816 4,801,112 Recent accounting pronouncements In November 2015, 2015 17, 740). 2015 17 December 15, 2016. On March 30, 2016, 2016 09, December 15, 2016, In February 2016, 2016 02, 2016 02 2016 02 December 15, 2018, In August 2016, 2016 15, “Statement of Cash Flows (Topic 230): 2016 15”). 2016 15 eight 2016 15 December 15, 2017. 2016 15 Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.	NOTE 3 Basis of Presentation The consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of PTI U.S.A, and its wholly owned subsidiary, PTI Canada. All significant intercompany transactions and balances have been eliminated from the consolidated financial statements. PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2015 AND 2014 NOTE 3 Foreign Currency Translation and Transactions The assets and liabilities of the Company’s foreign subsidiary PTI Canada are translated into U.S. dollars from its functional currency using the exchange rate in effect at the balance sheets date. Additionally, the accounts on the statements of operations are translated using exchange rates approximating average rates prevailing during the years. Equity accounts are translated at historical exchange rates. Translation adjustments that arise from translating its financial statements from the local currency to the U.S. dollar are accumulated and reflected as a separate component of stockholders’ deficit. The current year effect of the transaction adjustments are included on the statement of operations as a foreign currency exchange gain (loss). Use of Estimates In preparing consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amount of revenues and expenses during the reporting period. Significant estimates include accruals, contingencies, valuation allowance for deferred tax assets and valuation of stock options and warrants. These estimates may Cash and Cash Equivalents Cash equivalents consist of money market instruments with an original maturity at the time of purchase of three two one may Equipment Equipment was stated at cost less accumulated depreciation. Improvements and replacements of equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of equipment are charged to expense as incurred. When assets are retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss will be reported in the consolidated statements of operations. Depreciation is computed using straight- line methods over their estimated useful lives ranging from 3 5 PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2015 AND 2014 NOTE 3 OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) Rebates from Research and Development Credits The Company derives rebates from scientific research and experimental development tax credits issued by the Canada Revenue Agency for qualified expenditures. The credits are recognized when the rebate is issued. The amounts received are reinvested into the Company’s scientific research, experimental development and operational works conducted in Canada. Research and Development Expenses, net of Rebates The Company’s research and development expenditures for present and future products are expensed as incurred. Treasury Stock Management of the Company does not plan to retire the stock and applies the cost method to its treasury stock transactions. Differences between proceeds for reissuance of treasury stock and the cost are credited or charged to additional paid in capital to the extent of the prior credits and thereafter to accumulated deficit. Fair Value Measurements Accounting Standards Codification 820, 820”) 820 three 1) 3). The three Level 1 Level 2 Level 3 There were no transfers in or out of any level for the years ended December 31, 2015 2014. Cash and cash equivalents, accounts payable, and accrued expenses carry value equals approximately the fair value due to its short term nature. Based on the borrowing rates currently available to the Company for loans with similar terms and the expected short term maturity, the carrying value of the bridge note payable approximates fair value. PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2015 AND 2014 NOTE 3 OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) Stock-Based Compensation The Company accounts for stock based compensation costs under the provisions of ASC No. 718, Compensation—Stock Compensation 718. 718 718 Income Taxes The Company accounts for income taxes utilizing the liability method. Deferred income tax assets and liabilities are computed annually for differences between the consolidated financial statement basis and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such asset will be realized. Management has determined that a valuation allowance is required for the deferred tax assets which is primarily attributable to net operating loss carry forwards for federal and state tax purposes. The net operating losses expire through 2035 2022 Basic and Diluted Net (Loss) per Common Share Basic (loss) per common share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially dilutive securities consisting of options and warrants aggregating 5,111,111 4,371,111 December 31, 2015 2014, . PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2015 AND 2014 NOTE 3 Recent Accounting Pronouncements On March 30, 2016, 2016 09, December 15, 2016, In February 2016, 2016 02, Leases 2016 02 2016 02 December 15, 2018, In November 2015, 2015 17, Income taxes. 2015 17 December 15, 2016, In August 2014, 2014 15, 2014 15 (1) (2) (3) (4) (5) (6) one December 15, 2016, Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.

Note 4 - Accounts Payable and26

Note 4 - Accounts Payable and Accrued Expenses	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 4 ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of the following at: September 30, 2016 December 31, 2015 Legal $ 10,723 $ 186,936 Salaries - 41,166 Patent expense 31,315 29,239 Research and development 67,560 8,128 Payroll taxes and employee benefits - 6,222 Other 21,113 7,564 Accounting and tax expenses 857 - $ 131,568 $ 279,255	NOTE 4 Accounts payable and accrued expenses consist of the following as of December 31: 201 5 201 4 Legal expenses $ 186,936 $ 51,120 Salaries 41,166 -- Patent cost 29,239 87,244 Research and development 8,128 6,089 Payroll taxes and employee benefits 6,222 -- Other 4,841 1,280 $ 276,532 $ 145,733

Note 5 - Bridge Loans Payable -

Note 5 - Bridge Loans Payable - Stockholder	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 5 During January 1, 2015 February 12, 2016, $422,752 $1.25 10% $7,905 $0 nine September 30, 2016 2015, February 12, 2016, $350,000 $1.25 June 17, 2016, $75,265 $1.25	NOTE 5 The Company did not 2014. January 1, 2015 December 31, 2015, $399,103 $1.25 10% $11,473 December 31, 2015. December 31, 2015, $350,000 $1.25 June 2016, $1.25

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7 STOCKHOLDERS’ EQUITY (DEFICIT) On June 17, 2016, third July 27, 2016 one 15,463.7183 15,463.7183 one 100 100 $0.000001 $0.0001 5 20 Stock-Based Compensation In connection with the Merger, all of the issued and outstanding options to purchase shares of Prior Protagenic common stock converted, on a 1 1 New Options 2006 2006 The Plan is authorized to issue up to 2,000,000 one five ten There were 2,592,229 September 30, 2016. Expected dividend yield 0% Risk free interest rate 1.01% - 2.43% Expected life in years 5 Expected volatility 85% - 213% The following is an analysis of the stock option grant activity under the Plan: Exercise Weighted Average Number Price Exercise Price Stock Options Outstanding January 1, 2016 1,707,744 $ 0.84 Granted 1,301,084 $ 1.25 Expired (416,599 ) Outstanding September 30, 2016 2,592,229 $ 1.04 On February 12, 2016, 100,000 2006 $1.25 ten three 35 0.18 2,778 $10,383 $5,192 nine three September 30, 2016 March 31, 2016, On April 15, 2016, 40,000 5,000 10 24 $1.25 175,000 On April 15, 2016, 1,008,299 10 12 48 $1.25 During the quarter, 17,785 3 $1.25 The total number of options granted and vested during the nine September 30, 2016 1,974,445 133,229, 1,974,445 $1.25 The Company recognized compensation expense related to options issued of $450,566 nine September 30, 2016. On June 17, 2016, 2016 2006 8 June 20, 2016. Warrants: In connection with the Merger, all of the issued and outstanding warrants to purchase shares of Prior Protagenic common stock, converted, on a 1 1 New Warrants Simultaneous with the Merger and the Private Offering, New Warrants to purchase 3,403,367 $1.05 $665,000 $35,000 five 295,945 $1.25 127,346 $1.25 423,291 6. A summary of warrant issuances are as follows: Exercise Weighted Average Number Price Exercise Price Warrants Outstanding January 1, 2016 3,403,367 $ 1.05 Granted 423,291 $ 1.25 Outstanding September 30, 2016 3,826,658 $ 1.07	NOTE 6 Common Stock The Company adopted a certificate of amendment to the Company’s restated certificate of incorporation to increase the number of authorized shares of its $.001 10,000,000 20,000,000 October 2, 2015. No December 31, 2015 2014. Stock-Based Compensation On March 15, 2006, 2006 140,000 April 1, 2012, 2,000,000 one five ten December 31, 2015 2014, 490,000 240,000 $1.25 $1.00 2015 2014 six five one Management has determined that for each round of stock options granted, it was reasonable to estimate the fair value of the common stock options using the Black Scholes option pricing model. Accordingly, the Company has accounted for options using this calculated value method. Based on the fact that the Company is a privately held company with no revenue, management has estimated its expected future equity volatility factor in valuing the Company’s common stock equivalents by starting with its historical volatility adjusted for the volatility of equity interests from comparable publicly traded and privately held published companies to arrive at such industry benchmarks to evaluate. The fair value of each stock option granted and warrant issued during 2015 2014 2015 2014 Expected dividend yield 0% 0 % Risk free interest rate 1.66% - 2.43% 2.30 % Expected life in years 10 10 Expected volatility 85% 85 % No December 31, 2015 2014. December 31, 2015, no $190,751 $85,168 December 31, 2015 2014, Stock-Based Compensation (continued) As of December 31, 2015 2014, 292,256 782,256, December 31, 2015 $290,985, The following is an analysis of the stock option grant activity under the Plan: Exercise Weighted Average Number Price Exercise Price Stock Options Outstanding January 1, 2014 977,744 $ 0.60 Granted 240,000 $ 1.00 Outstanding December, 31, 2014 1,217,744 $ 0.68 Granted 490,000 $ 1.25 Outstanding December, 31, 2015 1,707,744 $ 0.84 The following is an analysis of the vested and non-vested stock options under the Plan as of December 31, 2015: Number of Options Expiration Date Remaining Contractual Life (Years) Exercise Price 104,150 March 1, 2016 0.17 $ 0.26 312,449 March 15, 2016 0.21 $ 0.26 55,000 August 1, 2016 0.59 $ 0.26 60,000 November 1, 2016 0.84 $ 0.26 21,145 February 1, 2017 1.09 $ 1.00 290,000 March 1, 2021 5.25 $ 1.00 10,000 June 10, 2021 5.45 $ 1.00 50,000 April 1, 2022 6.25 $ 1.00 75,000 December 1, 2022 6.92 $ 1.00 90,000 March 1, 2024 8.17 $ 1.00 215,000 March 1, 2025 9.17 $ 1.25 75,000 March 9, 2025 9.19 $ 1.25 150,000 March 1, 2027 11.17 $ 1.00 200,000 January 22, 2030 14.07 $ 1.25 1,707,744 Warrants The Company has conducted private placement offerings to raise financing since its formation. In connection with the private placement offerings that occurred in 2013, 2011, 2007, $1.00 $0.001 3 $1.00 ten The Company has warrants outstanding as follows: December 31, 2015 December 31, 2014 Financing and stock subscriptions (includes 300,000 warrants to the Major Stockholder and Chairman) 2,100,000 2,100,000 Consultants 350,000 100,000 Major Stockholder and Chairman 953,367 953,367 Total Warrants Issued 3,403,367 3,153,367 A summary of warrant issuances are as follows: Exercise Weighted Average Number Price Exercise Price Warrants Outstanding January 1, 2014 3,153,367 $ 1.01 Granted - $ - Outstanding December, 31, 2014 3,153,367 $ 1.00 Granted 250,000 $ 1.25 Outstanding December, 31, 2015 3,403,367 $ 1.05 All outstanding warrants are currently exercisable. A summary of warrants issued and outstanding at December 31, 2015 Number of Common Stock Equivalents Expiration Date Remaining Contractual Life(Years) Exercise Price 100,000 01/01/2017 1.2 $ 1.25 675,000 07/07/2021 5.5 to 6.7 $ 1.00 2,628,367 12/20/2023 7.3 to 8.1 $ 1.05 3,403,367 The Company recognized stock-based compensation expense pertaining to the warrants issued of $287,878 $0 December 31, 2015 2014, As of December 31, 2015, 1,253,367 417,789 $1.00 10 May 19, 2021 100,000 February18, 2023 317,789

Note 7 - Income Taxes

Note 7 - Income Taxes	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 7 The components of (loss) income before income taxes are as follows: 2015 2014 Domestic (747,693 ) 16,001 Foreign (275,729 ) (318,482 ) (Loss) income before income taxes (1,023,422 ) (302,481 ) The Company had no income tax expense due to operating losses incurred for the years ended December 31, 2015 2014. For the periods ended December 31, 2015 2014, 34% 2015 2014 Income taxes at Federal statutory rate -34.0 % -34.0 % State income taxes, net of Federal income tax effect -13.0 % -6.0 % Foreign tax rate differential 2.4 % 0.0 % Change in valuation allowance 43.5 % 40.0 % Other 1.1 % 0.0 % Income tax provision 0.0 % 0.0 % The tax effects of temporary differences that give rise to the Company’s deferred tax assets and liabilities are as follows: 2015 2014 U.S. net operating loss carryforwards 563,000 401,000 Stock compensation 206,000 - Canadian Provincial income tax losses 402,000 333,000 Canadian Provincial scientific investment tax credits 201,000 193,000 1,372,000 927,000 Valuation allowance (1,372,000 ) (927,000 ) Net deferred tax assets - - As of December 31, 2015 2014, $1,310,000 $1,041,000, 2024. 382 may December 31, 2015 2014, $1,303,000 $1,033,000, 2035. As of December 31, 2015 2014, $1,256,000 $980,000, 2026. December 31, 2015 2014, $201,000 $193,000, As a result of losses and uncertainty of future profit, the net deferred tax asset has been fully reserved. The net change in the valuation allowance during the years ended December 31, 2015 2014 $445,000 $67,000, Foreign earnings are assumed to be permanently reinvested. U.S. Federal income taxes have not been provided on undistributed earnings of our foreign subsidiary. The Company recognizes interest and penalties related to uncertain tax positions in selling, general and administrative expenses. The Company has not December 31, 2015 2014.

Note 8 - Collaborative Agreem30

Note 8 - Collaborative Agreements	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
In Process Research and Development [Member]
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 8 COLLABORATIVE AGREEMENTS The Company and the University of Toronto, a stockholder of the Company (the “University”) entered into an agreement effective December 14, 2004 March 31, 2013. The Company and the University entered into an agreement effective April 1, 2014 March 30, 2015. September 2015, September 30, 2016 Prior to January 1, 2016 25,000 $1.00 10 April 1, 2022. September 30, 2016 275,000 125,000 $1.00 10 13 March 30, 2021 March 1, 2027. The sponsorship research and development expenses pertaining to the Research Agreements were $3,000 $7,056 three September 30, 2016 2015, $4,500 $10,584 nine September 30, 2016,	NOTE 8 The Company and the University of Toronto, a stockholder of the Company (the “University”) entered into an agreement effective December 14, 2004 March 31, 2013. The Company and the University entered into an agreement effective April 1, 2014 March 31, 2015. September 2015, March 31, 2016 As of December 31, 2015 129,000 $.26 $1.00 10 March 15, 2016 April 1, 2022. December 31, 2015 483,299 62,500 $0.26 $1.00 10 13 March 15, 2016 March 1, 2027. The sponsorship research and development expenses were $170,575 $67,270 December 31, 2015 2014,

Note 9 - Licensing Agreements31

Note 9 - Licensing Agreements	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Licensing Agreements [Member]
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 9 LICENSING AGREEMENTS On July 31, 2005, February 18, 2015 Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% 10% September 9, 2006, 2.5% no nine September 30, 2016 2015 In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may 3% may may may 2.5% The patent applications were made in the name of the Professor and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the six	NOTE 9 On July 31, 2005, February 18, 2015 Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% 10% September 9, 2006, 2.5% no December 31, 2015 2014 In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may 3% may may may 2.5% The Company has incurred legal expense for research and development projects associated with the License Agreement and its amendment of $0 $25,287 December 31, 2015 2014, The Company also incurred patent costs for research and development projects associated with the License Agreement and its amendment of $22,435 60,434 December 31, 2015 2014, The patent applications were made in the name of the Professor and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the six

Note 10 - Commitments and Con32

Note 10 - Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 10 Consulting Agreement The Company had an employment agreement with its Officer/Related Party which expired on December 31, 2015. $6,489 December 31, 2015, 75,000 $64,223 $53,519 2015. As the agreement above expired, the Company issued a consulting agreement in its place that extended the majority of the terms of the employment agreement on a month-to-month basis. As a consultant, he is responsible for financial reporting, data compilation, and document retrieval services, reporting to the Chief Financial Officer, and to endeavor to secure non-dilutive grant funding for the Company. Prior to January 1, 2016, 250,000 $0.26, $1.00, $1.25 10 August 1, 2016 March 9, 2025. $2,000 2016 may fifteen (15) The Company has accrued $20,600 nine September 30, 2016 $0 three nine September 30, 2015. Consulting Agreement PTI Canada entered into a consulting agreement with a stockholder of the Company (the “Consultant”) which expired on December 31, 2015, December 31, 2016 January 1, 2016, 150,000 $1.00 $1.25 10 March 30, 2021 March 1, 2025. CA$3,000 may fifteen (15) The Company has accrued $18,122 three September 30, 2016 $1,619 three September 30, 2015. $67,161 nine September 30, 2016 $1,619 nine September 30, 2015. Legal Proceedings From time to time we may	NOTE 10 CONTINGENCIES Operating Lease with Related Party The Company paid its sole employee and officer, a related party, serving as the interim president and chief operating officer of PTI U.S.A. and a director and president and chief operating officer of PTI Canada (the “Officer/Related Party”), rent on the property which the Company is renting. The Company occupies roughly 1/3 1/3 December 31, 2015, $430 As of January 1, 2016 Employment Agreement The Company had an employment agreement with its sole employee the Officer/Related Party which expired on December 31, 2015. $6,489 December 31, 2015, 75,000 $64,223 $53,519 2015. Consulting Agreement PTI Canada entered into a consulting agreement with a stockholder of the Company, (the “Consultant”) which expired on December 31, 2015 December 31, 2015, 100,000 4,167 $1.00 10 March 30, 2021 March 1, 2024. $42,816 $35,680 2015. CA$1,000 may i.e. fifteen (15) The Company paid the Consultant $10,861 $11,650 December 31, 2015 2014, Legal Proceedings From time to time we may

Note 11 - Subsequent Events33

Note 11 - Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 11 SUBSEQUENT EVENTS The Company has evaluated the period after the balance sheet date up through the date that the condensed consolidated financial statements were filed, and determined that other than noted above, there were subsequent events or transactions that required recognition or disclosure in the condensed consolidated financial statements. At the October 26, 2016 one 25,000 $1.25 48 100,000 one 3 January 2017 January 2020.	NOTE 11 On February 12, 2016, Acquisition Corp. Atrinsic Merger Simultaneously with the Merger, on February 12, 2016, 1 1 $0.000001 Series B Preferred Stock February 12, 2016, 1 1 2006 February 12, 2016, one one 15,463.7183 Concurrently with the closing of the Merger, we conducted the first first 2,775,000 $1.25 $3,468,750. $350,000 $150,000 March 2, 2016 second 913,200 $1,141,500. April 15, 2016 420,260 $525,325. For all three $4,635,575 $4,283,438 $5,135,575 $4,783,438, $500,000 4,108,460 $159,183 $15,000 127,346 $1.25

Note 12 - Restatement of Previo

Note 12 - Restatement of Previously Issued Financial Statements	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Accounting Changes and Error Corrections [Text Block]	NOTE 12 Subsequent to the original issuance of the Company’s consolidated financial statements for the years ended December 31, 2014 2013, $179,098 2013. December 31, 2014 2013. 108, 2014 Balance Sheet Amounts Previously Reported Adjustment As Restated Additional paid in capital $ 5,580,548 $ (179,058 ) $ 5,401,490 Accumulated deficit $ (5,461,933 ) $ 179,058 $ (5,282,875 ) Statement of Cash Flows Amounts Previously Reported Adjustment As Restated Cash flows from operating activities: Stock based compensation $ 264,226 $ (179,058 ) $ 85,168 Effect of exchange rate on cash and cash equivalents $ (156,338 ) $ 179,058 $ 22,720

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the SEC for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2016 2015. The condensed consolidated financial statements include the accounts of Atrinsic, Inc., and its wholly owned subsidiary, Protagenic Acquisition Corp, and Protagenic Therapeutics, Inc., which was merged with and into Protagenic Acquisition Corp, on February 12, 2016, The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2015, December 31, 2015 2014 8 July 12, 2016. three nine September 30, 2016 December 31, 2016	Basis of Presentation The consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of PTI U.S.A, and its wholly owned subsidiary, PTI Canada. All significant intercompany transactions and balances have been eliminated from the consolidated financial statements.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include the allocation of the fair value of acquired assets and liabilities associated with the Merger, assessment of intangible assets, including goodwill and income tax provisions and allowances. The Company also relies on estimates for the valuation of stock-based compensation expense and financial instruments.	Use of Estimates In preparing consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amount of revenues and expenses during the reporting period. Significant estimates include accruals, contingencies, valuation allowance for deferred tax assets and valuation of stock options and warrants. These estimates may
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and indefinite-lived assets Goodwill and indefinite-lived assets are not amortized, but are evaluated for impairment annually or when indicators of a potential impairment are present. Our impairment testing of goodwill is performed separately from our impairment testing of indefinite-lived intangibles. The annual evaluation for impairment of goodwill and indefinite-lived intangibles is based on valuation models that incorporate assumptions and internal projections of expected future cash flows and operating plans. On the date of the Merger, the Company recorded the fair value of shares given to Predeccesor stockholders as Goodwill, and subsequent to the merger the Company determined that goodwill was impaired and wrote it down to zero. The allocation of the consideration transferred is as follows: Allocated to: Atrinsic 25,867 shares Common stock $ 32,334 Atrinsic Series A preferred stock as converted to Series B preferred stock, 297,468 shares 371,835 Total value of shares issued to Atrinsic on Merger date 404,169 Goodwill 404,169 Net value of consideration $ 0
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Accounting Standards Codification 820, 820”) 820 three 1) 3). The three Level 1 Level 2 Level 3 Cash equivalents consisting of money market funds are carried at cost which approximate fair value due to its short-term nature. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value as of September 30, 2016. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrant liabilities $ 516,757 $ — $ — $ 516,757 $ 516,757 The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) nine September 30, 2016: Fair Value Measurement Using Level 3 Inputs Total Balance, December 31, 2015 $ — Issuance of derivative warrants liabilities 487,425 Change in fair value of derivative warrant liabilities 29,332 Balance, September 30, 2016 $ 516,757 The fair value of the derivative feature of the 127,346 295,945 February 12 , 201 6 September 30 , 201 6 Risk free interest rate 1.20 % 1.14 % Dividend yield 0.00 % 0.00 % Expected volatility 156 % 213 % Contractual term (in years) 5.0 4.25 Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar term on the date of the grant. Dividend yield: The Company uses a 0% Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term. Remaining term: The Company’s remaining term is based on the remaining contractual maturity of the warrants. During the nine September 30, 2016, $29,332	Fair Value Measurements Accounting Standards Codification 820, 820”) 820 three 1) 3). The three Level 1 Level 2 Level 3 There were no transfers in or out of any level for the years ended December 31, 2015 2014. Cash and cash equivalents, accounts payable, and accrued expenses carry value equals approximately the fair value due to its short term nature. Based on the borrowing rates currently available to the Company for loans with similar terms and the expected short term maturity, the carrying value of the bridge note payable approximates fair value.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment The Company estimates the expected undiscounted future cash flows and operating plans and compares such amounts to the carrying amount of the goodwill to determine if the carrying amount is recoverable. If the carrying amount exceeds the estimated undiscounted future cash flows, the Company will adjust the carrying amount of the goodwill to the fair value. The factors used to determine fair value are subject to management’s judgement and expertise and include, but are not limited to, recent sales prices of comparable companies, the present value of future cash flows, anticipated capital expenditures and various discount rates commensurate with the risk and current market conditions associated with realizing the expected cash flows projected. These assumptions represent Level 3 nine September 30, 2016 $404,169.
Derivatives, Policy [Policy Text Block]	Derivative Liability The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with paragraph 815 10 05 4 815 40 25 The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 The Company utilizes a Black-Scholes option pricing model to compute the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The Company determined the fair value of the binomial lattice model and the Black-Scholes valuation model to be materially the same. The Company records the change in the fair value of the derivative as other income or expense in the consolidated statements of operations.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company has not begun planned principal operations and has not generated any revenue since inception.
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation Expenses The Company accounts for stock based compensation costs under the provisions of ASC No. 718, 718. 718 Stock-Based Compensation for Non-Employees The Company accounts for warrants and options issued to non-employees under ASC 505 50, Equity – Equity Based Payments to Non-Employees,	Stock-Based Compensation The Company accounts for stock based compensation costs under the provisions of ASC No. 718, Compensation—Stock Compensation 718. 718 718
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net (Loss) per Common Share Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. For the nine September 30, 2016 2015, 6,418,887 4,801,112, nine September 30, 2016 2015, 2,796,929 0, Potentially Outstanding Dilutive Common Shares For the Nine Months Ended September 30, 2016 For the Nine Months Ended September 30, 2015 Conversion Feature Shares Common shares issuable under the conversion feature of preferred shares 2,796,929 - Stock Option Shares 2,592,229 1,647,745 Warrant Shares 3,826,658 3,153,367 Total potentially outstanding dilutive common shares 9,215,816 4,801,112	Basic and Diluted Net (Loss) per Common Share Basic (loss) per common share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially dilutive securities consisting of options and warrants aggregating 5,111,111 4,371,111 December 31, 2015 2014,
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements In November 2015, 2015 17, 740). 2015 17 December 15, 2016. On March 30, 2016, 2016 09, December 15, 2016, In February 2016, 2016 02, 2016 02 2016 02 December 15, 2018, In August 2016, 2016 15, “Statement of Cash Flows (Topic 230): 2016 15”). 2016 15 eight 2016 15 December 15, 2017. 2016 15 Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.	Recent Accounting Pronouncements On March 30, 2016, 2016 09, December 15, 2016, In February 2016, 2016 02, Leases 2016 02 2016 02 December 15, 2018, In November 2015, 2015 17, Income taxes. 2015 17 December 15, 2016, In August 2014, 2014 15, 2014 15 (1) (2) (3) (4) (5) (6) one December 15, 2016, Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.
Foreign Currency Transactions and Translations Policy [Policy Text Block]		Foreign Currency Translation and Transactions The assets and liabilities of the Company’s foreign subsidiary PTI Canada are translated into U.S. dollars from its functional currency using the exchange rate in effect at the balance sheets date. Additionally, the accounts on the statements of operations are translated using exchange rates approximating average rates prevailing during the years. Equity accounts are translated at historical exchange rates. Translation adjustments that arise from translating its financial statements from the local currency to the U.S. dollar are accumulated and reflected as a separate component of stockholders’ deficit. The current year effect of the transaction adjustments are included on the statement of operations as a foreign currency exchange gain (loss).
Cash and Cash Equivalents, Policy [Policy Text Block]		Cash and Cash Equivalents Cash equivalents consist of money market instruments with an original maturity at the time of purchase of three two one may
Property, Plant and Equipment, Policy [Policy Text Block]		Equipment Equipment was stated at cost less accumulated depreciation. Improvements and replacements of equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of equipment are charged to expense as incurred. When assets are retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss will be reported in the consolidated statements of operations. Depreciation is computed using straight- line methods over their estimated useful lives ranging from 3 5
Research and Development Expense, Policy [Policy Text Block]		Rebates from Research and Development Credits The Company derives rebates from scientific research and experimental development tax credits issued by the Canada Revenue Agency for qualified expenditures. The credits are recognized when the rebate is issued. The amounts received are reinvested into the Company’s scientific research, experimental development and operational works conducted in Canada. Research and Development Expenses, net of Rebates The Company’s research and development expenditures for present and future products are expensed as incurred.
Stockholders' Equity, Policy [Policy Text Block]		Treasury Stock Management of the Company does not plan to retire the stock and applies the cost method to its treasury stock transactions. Differences between proceeds for reissuance of treasury stock and the cost are credited or charged to additional paid in capital to the extent of the prior credits and thereafter to accumulated deficit.
Income Tax, Policy [Policy Text Block]		Income Taxes The Company accounts for income taxes utilizing the liability method. Deferred income tax assets and liabilities are computed annually for differences between the consolidated financial statement basis and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such asset will be realized. Management has determined that a valuation allowance is required for the deferred tax assets which is primarily attributable to net operating loss carry forwards for federal and state tax purposes. The net operating losses expire through 2035 2022

Note 3 - Summary of Significa36

Note 3 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2016
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Allocated to: Atrinsic 25,867 shares Common stock $ 32,334 Atrinsic Series A preferred stock as converted to Series B preferred stock, 297,468 shares 371,835 Total value of shares issued to Atrinsic on Merger date 404,169 Goodwill 404,169 Net value of consideration $ 0
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrant liabilities $ 516,757 $ — $ — $ 516,757 $ 516,757
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair Value Measurement Using Level 3 Inputs Total Balance, December 31, 2015 $ — Issuance of derivative warrants liabilities 487,425 Change in fair value of derivative warrant liabilities 29,332 Balance, September 30, 2016 $ 516,757
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	February 12 , 201 6 September 30 , 201 6 Risk free interest rate 1.20 % 1.14 % Dividend yield 0.00 % 0.00 % Expected volatility 156 % 213 % Contractual term (in years) 5.0 4.25
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially Outstanding Dilutive Common Shares For the Nine Months Ended September 30, 2016 For the Nine Months Ended September 30, 2015 Conversion Feature Shares Common shares issuable under the conversion feature of preferred shares 2,796,929 - Stock Option Shares 2,592,229 1,647,745 Warrant Shares 3,826,658 3,153,367 Total potentially outstanding dilutive common shares 9,215,816 4,801,112

Note 4 - Accounts Payable and37

Note 4 - Accounts Payable and Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	September 30, 2016 December 31, 2015 Legal $ 10,723 $ 186,936 Salaries - 41,166 Patent expense 31,315 29,239 Research and development 67,560 8,128 Payroll taxes and employee benefits - 6,222 Other 21,113 7,564 Accounting and tax expenses 857 - $ 131,568 $ 279,255	201 5 201 4 Legal expenses $ 186,936 $ 51,120 Salaries 41,166 -- Patent cost 29,239 87,244 Research and development 8,128 6,089 Payroll taxes and employee benefits 6,222 -- Other 4,841 1,280 $ 276,532 $ 145,733

Note 7 - Stockholders' Equity38

Note 7 - Stockholders' Equity (Deficit) (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected dividend yield 0% Risk free interest rate 1.01% - 2.43% Expected life in years 5 Expected volatility 85% - 213%	2015 2014 Expected dividend yield 0% 0 % Risk free interest rate 1.66% - 2.43% 2.30 % Expected life in years 10 10 Expected volatility 85% 85 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Exercise Weighted Average Number Price Exercise Price Stock Options Outstanding January 1, 2016 1,707,744 $ 0.84 Granted 1,301,084 $ 1.25 Expired (416,599 ) Outstanding September 30, 2016 2,592,229 $ 1.04	Exercise Weighted Average Number Price Exercise Price Stock Options Outstanding January 1, 2014 977,744 $ 0.60 Granted 240,000 $ 1.00 Outstanding December, 31, 2014 1,217,744 $ 0.68 Granted 490,000 $ 1.25 Outstanding December, 31, 2015 1,707,744 $ 0.84
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Weighted Average Number Price Exercise Price Warrants Outstanding January 1, 2016 3,403,367 $ 1.05 Granted 423,291 $ 1.25 Outstanding September 30, 2016 3,826,658 $ 1.07	Exercise Weighted Average Number Price Exercise Price Warrants Outstanding January 1, 2014 3,153,367 $ 1.01 Granted - $ - Outstanding December, 31, 2014 3,153,367 $ 1.00 Granted 250,000 $ 1.25 Outstanding December, 31, 2015 3,403,367 $ 1.05

Note 4 - Accounts Payable and39

Note 4 - Accounts Payable and Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	September 30, 2016 December 31, 2015 Legal $ 10,723 $ 186,936 Salaries - 41,166 Patent expense 31,315 29,239 Research and development 67,560 8,128 Payroll taxes and employee benefits - 6,222 Other 21,113 7,564 Accounting and tax expenses 857 - $ 131,568 $ 279,255	201 5 201 4 Legal expenses $ 186,936 $ 51,120 Salaries 41,166 -- Patent cost 29,239 87,244 Research and development 8,128 6,089 Payroll taxes and employee benefits 6,222 -- Other 4,841 1,280 $ 276,532 $ 145,733

Note 6 - Stockholders' Deficit

Note 6 - Stockholders' Deficit (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected dividend yield 0% Risk free interest rate 1.01% - 2.43% Expected life in years 5 Expected volatility 85% - 213%	2015 2014 Expected dividend yield 0% 0 % Risk free interest rate 1.66% - 2.43% 2.30 % Expected life in years 10 10 Expected volatility 85% 85 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Exercise Weighted Average Number Price Exercise Price Stock Options Outstanding January 1, 2016 1,707,744 $ 0.84 Granted 1,301,084 $ 1.25 Expired (416,599 ) Outstanding September 30, 2016 2,592,229 $ 1.04	Exercise Weighted Average Number Price Exercise Price Stock Options Outstanding January 1, 2014 977,744 $ 0.60 Granted 240,000 $ 1.00 Outstanding December, 31, 2014 1,217,744 $ 0.68 Granted 490,000 $ 1.25 Outstanding December, 31, 2015 1,707,744 $ 0.84
Schedule of Nonvested Share Activity [Table Text Block]		Number of Options Expiration Date Remaining Contractual Life (Years) Exercise Price 104,150 March 1, 2016 0.17 $ 0.26 312,449 March 15, 2016 0.21 $ 0.26 55,000 August 1, 2016 0.59 $ 0.26 60,000 November 1, 2016 0.84 $ 0.26 21,145 February 1, 2017 1.09 $ 1.00 290,000 March 1, 2021 5.25 $ 1.00 10,000 June 10, 2021 5.45 $ 1.00 50,000 April 1, 2022 6.25 $ 1.00 75,000 December 1, 2022 6.92 $ 1.00 90,000 March 1, 2024 8.17 $ 1.00 215,000 March 1, 2025 9.17 $ 1.25 75,000 March 9, 2025 9.19 $ 1.25 150,000 March 1, 2027 11.17 $ 1.00 200,000 January 22, 2030 14.07 $ 1.25 1,707,744
Schedule of Warrants Outstanding [Table Text Block]		December 31, 2015 December 31, 2014 Financing and stock subscriptions (includes 300,000 warrants to the Major Stockholder and Chairman) 2,100,000 2,100,000 Consultants 350,000 100,000 Major Stockholder and Chairman 953,367 953,367 Total Warrants Issued 3,403,367 3,153,367
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Weighted Average Number Price Exercise Price Warrants Outstanding January 1, 2016 3,403,367 $ 1.05 Granted 423,291 $ 1.25 Outstanding September 30, 2016 3,826,658 $ 1.07	Exercise Weighted Average Number Price Exercise Price Warrants Outstanding January 1, 2014 3,153,367 $ 1.01 Granted - $ - Outstanding December, 31, 2014 3,153,367 $ 1.00 Granted 250,000 $ 1.25 Outstanding December, 31, 2015 3,403,367 $ 1.05
By Expiration Date [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]		Number of Common Stock Equivalents Expiration Date Remaining Contractual Life(Years) Exercise Price 100,000 01/01/2017 1.2 $ 1.25 675,000 07/07/2021 5.5 to 6.7 $ 1.00 2,628,367 12/20/2023 7.3 to 8.1 $ 1.05 3,403,367

Note 7 - Income Taxes (Tables)

Note 7 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	2015 2014 Domestic (747,693 ) 16,001 Foreign (275,729 ) (318,482 ) (Loss) income before income taxes (1,023,422 ) (302,481 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2015 2014 Income taxes at Federal statutory rate -34.0 % -34.0 % State income taxes, net of Federal income tax effect -13.0 % -6.0 % Foreign tax rate differential 2.4 % 0.0 % Change in valuation allowance 43.5 % 40.0 % Other 1.1 % 0.0 % Income tax provision 0.0 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2015 2014 U.S. net operating loss carryforwards 563,000 401,000 Stock compensation 206,000 - Canadian Provincial income tax losses 402,000 333,000 Canadian Provincial scientific investment tax credits 201,000 193,000 1,372,000 927,000 Valuation allowance (1,372,000 ) (927,000 ) Net deferred tax assets - -

Note 12 - Restatement of Prev42

Note 12 - Restatement of Previously Issued Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	Balance Sheet Amounts Previously Reported Adjustment As Restated Additional paid in capital $ 5,580,548 $ (179,058 ) $ 5,401,490 Accumulated deficit $ (5,461,933 ) $ 179,058 $ (5,282,875 ) Statement of Cash Flows Amounts Previously Reported Adjustment As Restated Cash flows from operating activities: Stock based compensation $ 264,226 $ (179,058 ) $ 85,168 Effect of exchange rate on cash and cash equivalents $ (156,338 ) $ 179,058 $ 22,720

Note 1 - Organization and Nat43

Note 1 - Organization and Nature of Business (Details Textual)	Jul. 27, 2016$ / sharesshares	Jun. 27, 2016$ / sharesshares	Apr. 15, 2016USD ($)$ / sharesshares	Mar. 02, 2016USD ($)shares	Feb. 13, 2016	Feb. 12, 2016USD ($)$ / sharesshares	Apr. 15, 2016USD ($)$ / sharesshares	Dec. 31, 2016shares	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)	Dec. 31, 2015$ / sharesshares	Dec. 31, 2014$ / sharesshares	Jul. 26, 2016shares	Jun. 26, 2016$ / sharesshares	Oct. 02, 2015$ / sharesshares	Oct. 01, 2015shares
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.000001								$ 0.000001		$ 0.000001
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									1,974,445		490,000	240,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares									$ 1.25		$ 1.25	$ 1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											1
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.0001	$ 0.0001				$ 0.0001			$ 0.0001		$ 0.0001	$ 0.001		$ 0.000001	$ 0.001
Number of Wholly-Owned Subsidiaries Split Off					29
Stock Issued During Period, Value, New Issues | $									$ 4,761,797
Stock Issued During Period, Value, Conversion of Convertible Securities | $									75,265
Warrants Issued for Settlement and Conversion of Debt | $									$ 340,784
Stock Shares Authorized	120,000,000
Common Stock, Shares Authorized	100,000,000	100,000,000							100,000,000		20,000,000	20,000,000		100,000,000,000	20,000,000	10,000,000
Preferred Stock, Shares Authorized	20,000,000	20,000,000							20,000,000		20,000,000			5,000,000,000
Stock Conversion from Series B Preferred Stock to Common Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion	1	1
Conversion of Stock, Shares Converted									8,221,837
Conversion of Stock, Shares Issued									8,221,837
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		15,463.7183
Scenario, Forecast [Member] | Stock Conversion from Series B Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted								1,924,163
Private Placement [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.25				$ 1.25
Private Placement [Member] | Commissions [Member]
Payments of Stock Issuance Costs | $			$ 159,183
Private Placement [Member] | Expense Allowance [Member]
Payments of Stock Issuance Costs | $			15,000
Private Placement [Member] | Legal and Miscellaneous Fees [Member]
Payments of Stock Issuance Costs | $			$ 266,727
Momspot LLC [Member]
Noncontrolling Interest, Ownership Percentage by Parent						51.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners						49.00%
Interest Ownership Split Off					51.00%
Investors in the Private Offering [Member]
Number of Common Stock Held As Converted Basis						2,775,000
Debt Principal Conversion to Predecessor Warrants [Member]
Debt Conversion, Original Debt, Amount | $						$ 665,000
Debt Interest Conversion to Predecessor Warrants [Member]
Debt Conversion, Original Debt, Amount | $						35,000
Conversion of Outstanding Stockholder Debt [Member] | Chairman and Board Member Garo H. Armen [Member]
Stock Issued During Period, Value, Conversion of Convertible Securities | $						350,000
Conversion of Outstanding Stockholder Debt [Member] | Predecessor's Stockholder [Member]
Stock Issued During Period, Value, Conversion of Convertible Securities | $						$ 150,000
Common Stock [Member]
Stock Issued During Period, Shares, Reverse Stock Split, Post-split						25,867
Stock Issued During Period, Value, New Issues | $
Stock Issued During Period, Value, Conversion of Convertible Securities | $									$ 6
Stock Issued During Period, Shares, New Issues											0	0
Series B Preferred Stock [Member]
Stock Issued During Period, Value, Conversion of Convertible Securities | $
Proceeds from Issuance of Convertible Preferred Stock | $									$ 4,283,437
Potential Percentage of Common Stock Owned by Shareholder	9.99%
Conversion of Stock, Shares Eligible for Conversion	10,146,000
Preferred Stock, Shares Outstanding									2,796,929		0		11,018,766
Conversion of Stock, Shares Eligible for Conversion, Shares to be Issued	10,146,000
Conversion of Stock, Remaining Shares to be Converted	872,766
Preferred Stock, Shares Authorized									18,000,000		18,000,000
Series B Preferred Stock [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	15,463.7183					15,463.7183
Series B Preferred Stock [Member] | Predecessor Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						295,945
Warrants Issued for Settlement and Conversion of Debt | $						$ 340,784
Series B Preferred Stock [Member] | Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						423,291
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1.25
Shares Issued, Price Per Share | $ / shares						$ 1.25
Stock Issued During Period, Value, New Issues | $						$ 3,468,750
Stock Issued During Period, Shares, New Issues			420,260	913,200		2,775,000	4,108,460
Proceeds from Issuance of Convertible Preferred Stock | $			$ 525,325	$ 1,141,500
Proceeds from Issuance of Private Placement | $							$ 4,635,575
Proceeds From Issuance of Private Placement, Net of Issuance Costs | $							4,283,438
Series B Preferred Stock [Member] | Private Placement [Member] | Including Conversion of Principal and Interest [Member]
Proceeds from Issuance of Private Placement | $							5,135,575
Proceeds From Issuance of Private Placement, Net of Issuance Costs | $							$ 4,783,438
Series B Preferred Stock [Member] | Private Placement [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			127,346				127,346
Class of Warrant or Right, Value of Securities Called by Warrants or Rights | $			$ 146,641				$ 146,641
Series B Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Value, Conversion of Convertible Securities | $									$ 822
Protagenic Therapeutics Inc [Member]
Business Acquisition, Conversion of Stock, Ratio						1
Business Combination, Stock Warrant Conversion Ratio						1
Stock Issued During Period, Shares, Conversion of Series A Preferred Stock to Series B Preferred Stock						297,468
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						127,346
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1.25
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						295,945
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1.25
Protagenic Therapeutics Inc [Member] | Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						3,403,367
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member]
Common Shares Exchanged for Preferred Shares						6,612,838
Preferred Stock, Par or Stated Value Per Share | $ / shares						$ 0.000001
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | New Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						1,807,744
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares						$ 0.87
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | New Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						3,403,367
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1.03
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | Predecessor Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						17,784
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares						$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						295,945
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1.25

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Net Income (Loss) Attributable to Parent	$ (455,476)	$ (439,477)	$ (586,387)	$ (1,719,749)	$ (586,387)	$ (1,023,422)	$ (302,481)
Retained Earnings (Accumulated Deficit)	(8,026,046)			(8,026,046)		(6,306,297)	$ (5,282,875)
Net Working Capital	$ 2,937,320			$ 2,937,320		$ (675,015)

Note 3 - Summary of Significa45

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Feb. 12, 2016	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Feb. 16, 2016
Goodwill, Fair Value Disclosure									$ 0
Fair Value Assumptions, Expected Dividend Rate					0.00%
Derivative, Gain (Loss) on Derivative, Net		$ (938)			$ (29,332)
Goodwill, Impairment Loss					$ 404,169
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					9,215,816	4,801,112
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					6,418,887	4,801,112	5,111,111	4,371,111
Convertible Preferred Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					2,796,929	0
Private Placement [Member] | Series B Preferred Stock [Member] | Strategic Bio Partners [Member] | Debt Settlement [Member]
Class of Warrant or Right, Issued	295,945
Private Placement [Member] | Series B Preferred Stock [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Issued	127,346

Note 3 - Allocation of Consider

Note 3 - Allocation of Consideration Transferred (Details) - Protagenic Therapeutics Inc [Member]	Feb. 12, 2016USD ($)
Total value of shares issued to Atrinsic on Merger date	$ 404,169
Goodwill	404,169
Net value of consideration	0
Common Stock [Member]
Atrinsic 25,867 shares Common stock	32,334
Preferred Stock [Member] | Series B Preferred Stock [Member]
Atrinsic 25,867 shares Common stock	$ 371,835

Note 3 - Allocation of Consid47

Note 3 - Allocation of Consideration Transferred (Details) (Parentheticals) - Protagenic Therapeutics Inc [Member]	Feb. 12, 2016shares
Stock Issued During Period, Shares, Conversion of Series A Preferred Stock to Series B Preferred Stock	297,468
Common Stock [Member]
Stock Issued During Period, Shares, Reverse Stock Split, Post-split	25,867
Preferred Stock [Member] | Series B Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Series A Preferred Stock to Series B Preferred Stock	297,468

Note 3 - Assets Measured at Fai

Note 3 - Assets Measured at Fair Value (Details) - Fair Value, Measurements, Recurring [Member]	Sep. 30, 2016USD ($)
Reported Value Measurement [Member]
Derivative warrant liabilities	$ 516,757
Estimate of Fair Value Measurement [Member]
Derivative warrant liabilities	516,757
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative warrant liabilities
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative warrant liabilities
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative warrant liabilities	$ 516,757

Note 3 - Changes in Fair Value

Note 3 - Changes in Fair Value for Assets and Liabilities Measured on a Recurring Basis (Details) - Derivative Financial Instruments, Liabilities [Member]	9 Months Ended
	Sep. 30, 2016USD ($)
Balance, December 31, 2015	$ 0
Issuance of derivative warrants liabilities	487,425
Change in fair value of derivative warrant liabilities	29,332
Balance, September 30, 2016	$ 516,757

Note 3 - Weighted Average Assum

Note 3 - Weighted Average Assumptions (Details)	Feb. 12, 2016	Sep. 30, 2016
Fair Value Assumptions, Expected Dividend Rate		0.00%
Derivative Financial Instruments, Liabilities [Member]
Risk free interest rate	1.20%	1.14%
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Expected volatility	156.00%	213.00%
Contractual term (in years) (Year)	5 years	4 years 91 days

Note 3 - Antidilutive Securitie

Note 3 - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Common shares issuable under the conversion feature of preferred shares (in shares)	9,215,816	4,801,112
Convertible Preferred Shares [Member]
Common shares issuable under the conversion feature of preferred shares (in shares)	2,796,929	0
Employee Stock Option [Member]
Common shares issuable under the conversion feature of preferred shares (in shares)	2,592,229	1,647,745
Warrant [Member]
Common shares issuable under the conversion feature of preferred shares (in shares)	3,826,658	3,153,367

Note 4 - Summary of Accounts Pa

Note 4 - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Legal	$ 10,723	$ 186,936	$ 51,120
Salaries		41,166
Patent expense	31,315	29,239	87,244
Research and development	67,560	8,128	6,089
Payroll taxes and employee benefits		6,222
Other	21,113	7,564	1,280
Accounting and tax expenses	857
	$ 131,568	$ 276,532	$ 145,733

Note 5 - Bridge Loan Payable 53

Note 5 - Bridge Loan Payable - Stockholder (Details Textual) - USD ($)	Jun. 17, 2016	Feb. 12, 2016	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Bridge Loan								$ 399,103	$ 0
Interest Expense						7,161	$ 11,473	11,473
Bridge Loan [Member]
Debt Instrument, Convertible, Conversion Price		$ 1.25
Chairman and Stockholder [Member]
Bridge Loan		$ 422,752						$ 399,103
Chairman and Stockholder [Member] | Bridge Loan [Member]
Debt Instrument, Convertible, Conversion Price	$ 1.25
Debt Instrument, Interest Rate, Stated Percentage		10.00%						10.00%
Interest Expense						$ 7,905	$ 0	$ 11,473
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 75,265	$ 350,000

Note 6 - Derivative Liabiliti54

Note 6 - Derivative Liabilities (Details Textual) - $ / shares	Feb. 12, 2016	Apr. 15, 2016	Dec. 31, 2015
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1
Private Placement [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.25
Private Placement [Member] | Series B Preferred Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.25
Class of Warrant or Right, Expiration Period	5 years
Private Placement [Member] | Series B Preferred Stock [Member] | Strategic Bio Partners [Member]
Class of Warrant or Right, Issued During Period	295,945
Private Placement [Member] | Series B Preferred Stock [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Issued During Period	127,346

Note 7 - Stockholders' Equity55

Note 7 - Stockholders' Equity (Deficit) (Details Textual)	Jul. 27, 2016$ / sharesshares	Jun. 27, 2016$ / sharesshares	Apr. 15, 2016$ / sharesshares	Feb. 12, 2016USD ($)$ / sharesshares	Apr. 01, 2012shares	Sep. 30, 2016$ / sharesshares	Mar. 31, 2016USD ($)	Sep. 30, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Jun. 26, 2016$ / sharesshares	Oct. 02, 2015$ / sharesshares	Oct. 01, 2015shares	Dec. 31, 2013shares	Mar. 15, 2006shares
Common Stock, Shares Authorized	100,000,000	100,000,000				100,000,000		100,000,000	20,000,000	20,000,000	100,000,000,000	20,000,000	10,000,000
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.0001	$ 0.0001		$ 0.0001		$ 0.0001		$ 0.0001	$ 0.0001	$ 0.001	$ 0.000001	$ 0.001
Preferred Stock, Shares Authorized	20,000,000	20,000,000				20,000,000		20,000,000	20,000,000		5,000,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						2,592,229		2,592,229	1,707,744	1,217,744				977,744
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								1,974,445	490,000	240,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares								$ 1.25	$ 1.25	$ 1
Allocated Share-based Compensation Expense | $								$ 450,566
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares								133,229
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 1
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized						18,000,000		18,000,000	18,000,000
Predecessor Warrants [Member] | Series B Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				295,945
Private Placement [Member] | Series B Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				423,291
Class of Warrant or Right, Expiration Period				5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.25
Private Placement [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.25
Private Placement [Member] | Placement Agent Warrants [Member] | Series B Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			127,346
Protagenic Therapeutics Inc [Member]
Business Combination, Stock Warrant Conversion Ratio				1
Debt Instrument, Face Amount | $				$ 665,000
Debt Instrument, Increase, Accrued Interest | $				$ 35,000
Class of Warrant or Right, Expiration Period				5 years
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				295,945
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.25
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				127,346
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.25
Protagenic Therapeutics Inc [Member] | Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				3,403,367
Each Member of Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			40,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares			$ 1.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Additional			5,000
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			175,000
Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,008,299
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares			$ 1.25
Former Executives [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						17,785
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares								$ 1.25
Employee Stock Option [Member]
Allocated Share-based Compensation Expense | $									$ 190,751	$ 85,168
Employee Stock Option [Member] | Each Member of Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			2 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Employee Stock Option [Member] | Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
Employee Stock Option [Member] | Former Executives [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								3 years
Employee Stock Option [Member] | Minimum [Member] | Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Employee Stock Option [Member] | Maximum [Member] | Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			1 year
The 2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number						2,592,229		2,592,229	292,256	782,256
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									490,000	240,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares									$ 1.25	$ 1
The 2006 Plan [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				100,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares				$ 1.25
The 2006 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					2,000,000	2,000,000		2,000,000							140,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								5 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years	10 years
The 2006 Plan [Member] | Employee Stock Option [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Number of Monthly Installments				35
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Monthly Installment, Shares				0.18
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Final Monthly Installment, Shares				2,778
Allocated Share-based Compensation Expense | $							$ 5,192	$ 10,383
The 2006 Plan [Member] | Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					1 year			1 year	180 days
The 2006 Plan [Member] | Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					5 years				5 years
Stock Conversion from Series B Preferred Stock to Common Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion	1	1
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		15,463.7183
Reverse Stock Split [Member] | Series B Preferred Stock [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	15,463.7183			15,463.7183

Note 7 - Fair Value Assumptions

Note 7 - Fair Value Assumptions (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Expected dividend yield	0.00%	0.00%	0.00%
Risk free interest rate			2.30%
Expected life in years (Year)	5 years	10 years	10 years
Expected volatility		85.00%	85.00%
Minimum [Member]
Risk free interest rate	1.01%	1.66%
Expected volatility	85.00%
Maximum [Member]
Risk free interest rate	2.43%	2.43%
Expected volatility	213.00%

Note 7 - Stock Option Grant Act

Note 7 - Stock Option Grant Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Outstanding January 1, 2016 (in shares)	1,707,744	1,217,744	977,744
Outstanding January 1, 2016 (in dollars per share)	$ 0.84	$ 0.68	$ 0.60
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,974,445	490,000	240,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.25	$ 1.25	$ 1
Expired (in shares)	(416,599)
Outstanding September 30, 2016 (in shares)	2,592,229	1,707,744	1,217,744
Outstanding September 30, 2016 (in dollars per share)	$ 1.04	$ 0.84	$ 0.68

Note 7 - Summary of Warrants (D

Note 7 - Summary of Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Outstanding January 1, 2016 (in shares)	3,403,367	3,153,367	3,153,367
Outstanding January 1, 2016 (in dollars per share)	$ 1.05	$ 1	$ 1.01
Granted (in shares)	423,291	250,000
Granted (in dollars per share)	$ 1.25	$ 1.25
Outstanding September 30, 2016 (in shares)	3,826,658	3,403,367	3,153,367
Outstanding September 30, 2016 (in dollars per share)	$ 1.07	$ 1.05	$ 1

Note 8 - Collaborative Agreem59

Note 8 - Collaborative Agreements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended		133 Months Ended	142 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares						1,707,744		1,707,744
Research and Development Expense	$ 114,941	$ 203,814	$ 265,238	$ 537,662		$ 456,274	$ 191,069
In Process Research and Development [Member]
Research and Development Expense	$ 3,000	$ 7,056		$ 4,500	$ 10,584
University of Toronto [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures								25,000
University of Toronto [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price						$ 1		$ 1
University of Toronto [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price						0.26		$ 0.26
University of Toronto [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Professor [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures								483,299	275,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price						$ 1		$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	125,000			125,000		62,500		62,500	125,000
Professor [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1			$ 1		$ 1		$ 1	$ 1
Professor [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price						$ 0.26		$ 0.26
Professor [Member] | Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								13 years	13 years
Professor [Member] | Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years	10 years

Note 9 - Licensing Agreements (

Note 9 - Licensing Agreements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Revenues				$ 0	$ 0	$ 0	$ 0
Licensing Agreements [Member]
Royalty Payment, Percentage	2.50%			2.50%		2.50%
Up-front Sub-license Fees, Percentage	10.00%			10.00%		10.00%
Interest on Amounts Owed Under License Agreement, Rate	3.00%			3.00%		3.00%

Note 10 - Commitments and Con61

Note 10 - Commitments and Contingencies (Details Textual)	3 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016CAD	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)	Sep. 30, 2015USD ($)
Allocated Share-based Compensation Expense		$ 450,566
Employee Stock Option [Member]
Allocated Share-based Compensation Expense				$ 190,751	$ 85,168
Officer [Member] | Employment Agreement [Member]
Monthly Salary Agreement Amount				$ 6,489
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares				75,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Value				$ 64,223
Allocated Share-based Compensation Expense				$ 53,519
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares				250,000
Compensation of Rendered Service	$ 2,000
Accrued Salaries		20,600				$ 0
Officer [Member] | Employment Agreement [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Officer [Member] | Employment Agreement [Member] | Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares				$ 0.26
Officer [Member] | Employment Agreement [Member] | Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares				1
Officer [Member] | Employment Agreement [Member] | Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares				$ 1.25
Stockholder [Member] | Consulting Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares				150,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Compensation of Rendered Service | CAD			CAD 3,000
Accrued Salaries		1,619
Increase (Decrease) in Accrued Salaries		18,122
Compensation		$ 1,619
Stockholder [Member] | Consulting Agreement [Member] | Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares				$ 1
Stockholder [Member] | Consulting Agreement [Member] | Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares				$ 1.25

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - $ / shares	Oct. 26, 2016	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,974,445	490,000	240,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 1.25	$ 1.25	$ 1
Subsequent Event [Member] | Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	25,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.25
Subsequent Event [Member] | Employee [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	48 years
Subsequent Event [Member] | Former Consultant [Member]
Class of Warrant or Right, Extension, Number of Warrants	100,000
Class of Warrant or Right, Extension Period	3 years

Note 2 - Liquidity (Details T63

Note 2 - Liquidity (Details Textual) - USD ($)	Apr. 16, 2016	Apr. 15, 2016	Apr. 15, 2016	Sep. 30, 2016	Apr. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net Income (Loss) Attributable to Parent				$ (455,476)		$ (439,477)	$ (586,387)	$ (1,719,749)	$ (586,387)		$ (1,023,422)	$ (302,481)
Retained Earnings (Accumulated Deficit)				(8,026,046)				(8,026,046)			(6,306,297)	$ (5,282,875)
Net Working Capital				$ 2,937,320				$ 2,937,320			$ (675,015)
Scenario, Forecast [Member]
Effect on Future Cash Flows, Amount										$ 2,691,000
Private Placement [Member] | Series B Preferred Stock [Member]
Proceeds from Issuance of Private Placement			$ 4,635,575
Proceeds From Issuance of Private Placement, Net of Issuance Costs			4,283,438
Private Placement [Member] | Including Conversion of Principal and Interest [Member] | Series B Preferred Stock [Member]
Proceeds from Issuance of Private Placement			5,135,575
Proceeds From Issuance of Private Placement, Net of Issuance Costs			$ 4,783,438
Subsequent Event [Member] | Series B Preferred Stock [Member]
Proceeds from Issuance of Private Placement		$ 525,325
Subsequent Event [Member] | Private Placement [Member]
Proceeds from Issuance of Private Placement	$ 4,635,575
Proceeds From Issuance of Private Placement, Net of Issuance Costs	$ 4,283,438
Subsequent Event [Member] | Private Placement [Member] | Including Conversion of Principal and Interest [Member] | Series B Preferred Stock [Member]
Proceeds from Issuance of Private Placement					$ 4,635,575
Proceeds From Issuance of Private Placement, Net of Issuance Costs					$ 4,283,438

Note 3 - Summary of Significa64

Note 3 - Summary of Significant Accounting Policies (Details Textual) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,215,816	4,801,112
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,418,887	4,801,112	5,111,111	4,371,111
Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years

Note 4 - Summary of Accounts 65

Note 4 - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Legal expenses	$ 10,723	$ 186,936	$ 51,120
Salaries		41,166
Patent expense	31,315	29,239	87,244
Research and development	67,560	8,128	6,089
Payroll taxes and employee benefits		6,222
Other	21,113	7,564	1,280
	$ 131,568	$ 276,532	$ 145,733

Note 5 - Bridge Loans Payable66

Note 5 - Bridge Loans Payable - Stockholder (Details Textual) - USD ($)	Jun. 17, 2016	Feb. 12, 2016	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Bridge Loan									$ 399,103	$ 0
Interest Expense							7,161	$ 11,473	11,473
Bridge Loan [Member]
Debt Instrument, Convertible, Conversion Price		$ 1.25
Chairman and Stockholder [Member]
Bridge Loan		$ 422,752							$ 399,103
Chairman and Stockholder [Member] | Bridge Loan [Member]
Debt Instrument, Convertible, Conversion Price	$ 1.25
Debt Instrument, Interest Rate, Stated Percentage		10.00%							10.00%
Interest Expense							$ 7,905	$ 0	$ 11,473
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 75,265	$ 350,000
Chairman and Stockholder [Member] | Bridge Loan [Member] | Common Stock [Member]
Debt Instrument, Convertible, Conversion Price									$ 1.25
Chairman and Stockholder [Member] | Bridge Loan [Member] | Common Stock [Member] | Subsequent Event [Member]
Debt Instrument, Convertible, Conversion Price					$ 1.25
Chairman and Stockholder [Member] | Bridge Loan, Principal [Member] | Common Stock [Member] | Subsequent Event [Member]
Debt Instrument, Convertible, Conversion Price					$ 1.25
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments					$ 350,000

Note 6 - Stockholders' Defici67

Note 6 - Stockholders' Deficit (Details Textual) - USD ($)	Apr. 01, 2012	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014	Feb. 18, 2023	May 19, 2021	Jul. 27, 2016	Jun. 27, 2016	Jun. 26, 2016	Feb. 12, 2016	Oct. 02, 2015	Oct. 01, 2015	Dec. 31, 2013	Mar. 15, 2006
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001	$ 0.001			$ 0.0001	$ 0.0001	$ 0.000001	$ 0.0001	$ 0.001
Common Stock, Shares Authorized		100,000,000	20,000,000	20,000,000			100,000,000	100,000,000	100,000,000,000		20,000,000	10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,974,445	490,000	240,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 1.25	$ 1.25	$ 1
Allocated Share-based Compensation Expense		$ 450,566
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		2,592,229	1,707,744	1,217,744									977,744
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			3
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1
Class of Warrant or Right, Exercise Period			10 years
Major Stockholder and Chairman [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1
Class of Warrant or Right, Exercise Period			10 years
Class of Warrant or Right, Issued			1,253,367
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			417,789
Major Stockholder and Chairman [Member] | Scenario, Forecast [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					317,789	100,000
Employee Stock Option [Member]
Allocated Share-based Compensation Expense			$ 190,751	$ 85,168
Warrant [Member]
Common Stock, Par or Stated Value Per Share			$ 0.001
Allocated Share-based Compensation Expense			$ 287,878	$ 0
Shares Issued, Price Per Share			$ 1
The 2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			490,000	240,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 1.25	$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period			0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value			$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		2,592,229	292,256	782,256
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 290,985
The 2006 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,000,000	2,000,000												140,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years	10 years
The 2006 Plan [Member] | Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year	1 year	180 days
The 2006 Plan [Member] | Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years		5 years
Common Stock [Member]
Stock Issued During Period, Shares, New Issues			0	0

Note 6 - Fair Value Assumption

Note 6 - Fair Value Assumption (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Expected dividend yield	0.00%	0.00%	0.00%
Risk free interest rate			2.30%
Expected life in years (Year)	5 years	10 years	10 years
Expected volatility		85.00%	85.00%
Minimum [Member]
Risk free interest rate	1.01%	1.66%
Expected volatility	85.00%
Maximum [Member]
Risk free interest rate	2.43%	2.43%
Expected volatility	213.00%

Note 6 - Stock Option Grant Act

Note 6 - Stock Option Grant Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Outstanding January 1, 2016 (in shares)	1,707,744	1,217,744	977,744
Outstanding January 1, 2016 (in dollars per share)	$ 0.84	$ 0.68	$ 0.60
Granted (in shares)	1,974,445	490,000	240,000
Granted (in dollars per share)	$ 1.25	$ 1.25	$ 1
Outstanding September 30, 2016 (in shares)	2,592,229	1,707,744	1,217,744
Outstanding September 30, 2016 (in dollars per share)	$ 1.04	$ 0.84	$ 0.68

Note 6 - Analysis of Non-vested

Note 6 - Analysis of Non-vested Stock Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2016	Dec. 31, 2014	Dec. 31, 2013
Number of Options (in shares)	1,707,744
Exercise Price (in dollars per share)	$ 0.84	$ 1.04	$ 0.68	$ 0.60
Non-Vested Stock Options 1 [Member]
Number of Options (in shares)	104,450
Remaining Contractual Life (Year)	62 days
Exercise Price (in dollars per share)	$ 0.26
Non-Vested Stock Options 2 [Member]
Number of Options (in shares)	312,449
Remaining Contractual Life (Year)	76 days
Exercise Price (in dollars per share)	$ 0.26
Non-Vested Stock Options 3 [Member]
Number of Options (in shares)	55,000
Remaining Contractual Life (Year)	215 days
Exercise Price (in dollars per share)	$ 0.26
Non-Vested Stock Options 4 [Member]
Number of Options (in shares)	60,000
Remaining Contractual Life (Year)	306 days
Exercise Price (in dollars per share)	$ 0.26
Non-Vested Stock Options 5 [Member]
Number of Options (in shares)	21,146
Remaining Contractual Life (Year)	1 year 32 days
Exercise Price (in dollars per share)	$ 1
Non-Vested Stock Options 6 [Member]
Number of Options (in shares)	290,000
Remaining Contractual Life (Year)	5 years 91 days
Exercise Price (in dollars per share)	$ 1
Non-Vested Stock Options 7 [Member]
Number of Options (in shares)	10,000
Remaining Contractual Life (Year)	5 years 164 days
Exercise Price (in dollars per share)	$ 1
Non-Vested Stock Options 8 [Member]
Number of Options (in shares)	50,000
Remaining Contractual Life (Year)	6 years 91 days
Exercise Price (in dollars per share)	$ 1
Non-Vested Stock Options 9 [Member]
Number of Options (in shares)	75,000
Remaining Contractual Life (Year)	6 years 335 days
Exercise Price (in dollars per share)	$ 1
Non-Vested Stock Options 10 [Member]
Number of Options (in shares)	90,000
Remaining Contractual Life (Year)	8 years 62 days
Exercise Price (in dollars per share)	$ 1
Non-Vested Stock Options 11 [Member]
Number of Options (in shares)	215,000
Remaining Contractual Life (Year)	9 years 62 days
Exercise Price (in dollars per share)	$ 1.25
Non-Vested Stock Options 12 [Member]
Number of Options (in shares)	75,000
Remaining Contractual Life (Year)	9 years 69 days
Exercise Price (in dollars per share)	$ 1.25
Non-Vested Stock Options 13 [Member]
Number of Options (in shares)	150,000
Remaining Contractual Life (Year)	11 years 62 days
Exercise Price (in dollars per share)	$ 1
Non-Vested Stock Options 14 [Member]
Number of Options (in shares)	200,000
Remaining Contractual Life (Year)	14 years 25 days
Exercise Price (in dollars per share)	$ 1.25

Note 6 - Warrants Outstanding (

Note 6 - Warrants Outstanding (Details) - shares	Dec. 31, 2015	Dec. 31, 2014
Warrants Outstanding (in shares)	3,403,367	3,153,367
Warrant Issued for Financing and Stock Subscriptions [Member]
Warrants Outstanding (in shares)	2,100,000	2,100,000
Warrants Issued to Consultants [Member]
Warrants Outstanding (in shares)	350,000	100,000
Warrants Issued to a Major Stockholder and Chairman [Member]
Warrants Outstanding (in shares)	953,367	953,367

Note 6 - Warrants Outstanding72

Note 6 - Warrants Outstanding (Details) (Parentheticals) - shares	Dec. 31, 2015	Dec. 31, 2014
Warrants Outstanding (in shares)	3,403,367	3,153,367
Warrant Issued for Financing and Stock Subscriptions [Member]
Warrants Outstanding (in shares)	2,100,000	2,100,000
Warrant Issued for Financing and Stock Subscriptions [Member] | Major Stockholder and Chairman [Member]
Warrants Outstanding (in shares)	300,000	300,000

Note 6 - Summary of Warrants (D

Note 6 - Summary of Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Outstanding January 1, 2016 (in shares)	3,403,367	3,153,367	3,153,367
Outstanding January 1, 2016 (in dollars per share)	$ 1.05	$ 1	$ 1.01
Granted (in shares)	423,291	250,000
Granted (in dollars per share)	$ 1.25	$ 1.25
Outstanding September 30, 2016 (in shares)	3,826,658	3,403,367	3,153,367
Outstanding September 30, 2016 (in dollars per share)	$ 1.07	$ 1.05	$ 1

Note 6 - Summary of Warrants Is

Note 6 - Summary of Warrants Issued and Outstanding (Details)	12 Months Ended
	Dec. 31, 2015$ / shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1
Expires on January 1, 2017 [Member]
Remaining Contractual Life (Year)	1 year 73 days
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.25
Expires on July 7, 2021 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1
Expires on July 7, 2021 [Member] | Minimum [Member]
Remaining Contractual Life (Year)	5 years 182 days
Expires on July 7, 2021 [Member] | Maximum [Member]
Remaining Contractual Life (Year)	6 years 255 days
Expires on December 20, 2023 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.05
Expires on December 20, 2023 [Member] | Minimum [Member]
Remaining Contractual Life (Year)	7 years 109 days
Expires on December 20, 2023 [Member] | Maximum [Member]
Remaining Contractual Life (Year)	8 years 36 days

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$ 445,000	$ 67,000
Unrecognized Tax Benefits	0	0
Domestic Tax Authority [Member]
Operating Loss Carryforwards	1,310,000	1,041,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	1,303,000	1,033,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards	1,256,000	980,000
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	$ 201,000	$ 193,000

Note 7 - Components of (Loss) I

Note 7 - Components of (Loss) Income before Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Domestic	$ (747,693)	$ 16,001
Foreign	(275,729)	(318,482)
(Loss) income before income taxes	$ (1,023,422)	$ (302,481)

Note 7 - Effective Tax Expense

Note 7 - Effective Tax Expense (Benefit) (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income taxes at Federal statutory rate	(34.00%)	(34.00%)
State income taxes, net of Federal income tax effect	(13.00%)	(6.00%)
Foreign tax rate differential	2.40%	0.00%
Change in valuation allowance	43.50%	40.00%
Other	1.10%	0.00%
Income tax provision	0.00%	0.00%

Note 7 - Deferred Tax Assets an

Note 7 - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
U.S. net operating loss carryforwards	$ 563,000	$ 401,000
Stock compensation	206,000
	1,372,000	927,000
Valuation allowance	(1,372,000)	(927,000)
Net deferred tax assets
Foreign Tax Authority [Member]
Canadian Provincial income tax losses	402,000	333,000
Canadian Provincial scientific investment tax credits	$ 201,000	$ 193,000

Note 8 - Collaborative Agreem79

Note 8 - Collaborative Agreements (Details Textual) - USD ($)	12 Months Ended		133 Months Ended	142 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	1,707,744		1,707,744
Research and Development Expense, Sponsored Research	$ 170,575	$ 67,270
University of Toronto [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures			25,000
University of Toronto [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
University of Toronto [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.26		$ 0.26
University of Toronto [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	1		$ 1
Professor [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures			483,299	275,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1		$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	62,500		62,500	125,000
Professor [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.26		$ 0.26
Professor [Member] | Minimum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years	10 years
Professor [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 1		$ 1	$ 1
Professor [Member] | Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			13 years	13 years

Note 9 - Licensing Agreements80

Note 9 - Licensing Agreements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Revenues				$ 0	$ 0	$ 0	$ 0
Research and Development Expense, Legal Fees						164,855	25,287
Research and Development Expense, Patents						$ 22,435	60,434
Licensing Agreements [Member]
Royalty Payment, Percentage	2.50%			2.50%		2.50%
Up-front Sub-license Fees, Percentage	10.00%			10.00%		10.00%
Interest on Amounts Owed Under License Agreement, Rate	3.00%			3.00%		3.00%
Research and Development Expense, Legal Fees						$ 0	25,287
Research and Development Expense, Patents						$ 22,435	$ 60,434

Note 10 - Commitments and Con81

Note 10 - Commitments and Contingencies (Details Textual)	3 Months Ended		6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Sep. 30, 2016USD ($)shares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2015CADshares	Dec. 31, 2014USD ($)
Operating Leases, Rent Expense					$ 430
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares				133,229
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares					1,707,744
Research and Development Expense	$ 114,941	$ 203,814	$ 265,238	$ 537,662	$ 456,274		$ 191,069
Employment [Member]
Compensation					$ 6,489
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares					75,000	75,000
Stock Issued During Period, Value, Stock Options Exercised					$ 64,223
Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)					53,519
Consultant [Member]
Compensation | CAD						CAD 1,000
Stock Issued During Period, Value, Stock Options Exercised					42,816
Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)					$ 35,680
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares					100,000	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares					4,167
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares					$ 1
Research and Development Expense					$ 10,861		$ 11,650
Consultant [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term					10 years	10 years

Note 11 - Subsequent Events (82

Note 11 - Subsequent Events (Details Textual)	Jul. 27, 2016$ / shares	Jun. 27, 2016	Apr. 16, 2016USD ($)$ / sharesshares	Apr. 15, 2016USD ($)shares	Mar. 02, 2016USD ($)shares	Feb. 12, 2016USD ($)$ / sharesshares	Apr. 15, 2016USD ($)shares	Sep. 30, 2016USD ($)$ / shares	Sep. 30, 2015USD ($)	Dec. 31, 2015$ / shares
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.000001							$ 0.000001		$ 0.000001
Stock Issued During Period, Value, New Issues								$ 4,761,797
Stock Issued During Period, Value, Conversion of Convertible Securities								75,265
Conversion of Outstanding Stockholder Debt [Member] | Predecessor's Stockholder [Member]
Stock Issued During Period, Value, Conversion of Convertible Securities						$ 150,000
Conversion of Outstanding Stockholder Debt [Member] | Chairman and Board Member Garo H. Armen [Member]
Stock Issued During Period, Value, Conversion of Convertible Securities						$ 350,000
Private Placement [Member] | Subsequent Event [Member]
Proceeds from Issuance of Private Placement			$ 4,635,575
Proceeds From Issuance of Private Placement, Net of Issuance Costs			4,283,438
Private Placement Offering [Member] | Subsequent Event [Member]
Stock Issued During Period, Value, Conversion of Convertible Securities			500,000
Proceeds from Issuance of Private Placement			5,135,575
Proceeds From Issuance of Private Placement, Net of Issuance Costs			4,783,438
Placement Agent Warrants [Member] | Subsequent Event [Member]
Payments for Commissions			159,183
Cost and Expense Allowance			$ 15,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		15,463.7183
Series B Preferred Stock [Member]
Stock Issued During Period, Value, Conversion of Convertible Securities
Proceeds from Issuance of Convertible Preferred Stock								$ 4,283,437
Series B Preferred Stock [Member] | Subsequent Event [Member]
Proceeds from Issuance of Private Placement				$ 525,325
Series B Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues | shares				420,260	913,200	2,775,000	4,108,460
Shares Issued, Price Per Share | $ / shares						$ 1.25
Stock Issued During Period, Value, New Issues						$ 3,468,750
Proceeds from Issuance of Convertible Preferred Stock				$ 525,325	$ 1,141,500
Proceeds from Issuance of Private Placement							$ 4,635,575
Proceeds From Issuance of Private Placement, Net of Issuance Costs							$ 4,283,438
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						423,291
Series B Preferred Stock [Member] | Private Placement [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues | shares				420,260
Series B Preferred Stock [Member] | Private Placement Offering [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues | shares			4,108,460
Series B Preferred Stock [Member] | Placement Agent Warrants [Member] | Subsequent Event [Member]
Preferred Stock, Par or Stated Value Per Share | $ / shares			$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			127,346
Series B Preferred Stock [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	15,463.7183					15,463.7183
Protagenic Therapeutics Inc [Member]
Business Acquisition, Conversion of Stock, Ratio						1
Business Combination, Stock Warrant Conversion Ratio						1
Protagenic Therapeutics Inc [Member] | Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						3,403,367
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share | $ / shares						$ 0.000001

Note 12 - Restatement of Prev83

Note 12 - Restatement of Previously Issued Financial Statements (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation	$ 450,566	$ 358,972	$ 478,629	$ 85,168
Restatement Adjustment [Member]
Share-based Compensation				$ (179,058)

Note 12 - Restated Financial St

Note 12 - Restated Financial Statements (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Additional paid in capital	$ 11,137,911		$ 5,880,119	$ 5,401,490
Retained Earnings (Accumulated Deficit)	(8,026,046)		(6,306,297)	(5,282,875)
Cash flows from operating activities:
Share-based Compensation	450,566	$ 358,972	478,629	85,168
Effect of exchange rate on cash and cash equivalents	$ (18,291)	$ (17,916)	$ (23,888)	22,720
Scenario, Previously Reported [Member]
Additional paid in capital				5,580,548
Retained Earnings (Accumulated Deficit)				(5,461,933)
Cash flows from operating activities:
Share-based Compensation				264,226
Effect of exchange rate on cash and cash equivalents				(156,338)
Restatement Adjustment [Member]
Additional paid in capital				(179,058)
Retained Earnings (Accumulated Deficit)				179,058
Cash flows from operating activities:
Share-based Compensation				(179,058)
Effect of exchange rate on cash and cash equivalents				$ 179,058